Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Neoplasms of the CNS

  Free Subscription


Articles published in Neuro Oncol

Retrieve available abstracts of 451 articles:
HTML format



Single Articles


    October 2021
  1. PANT A, Lim M
    Checkpoint blockade in recurrent meningiomas: Lessons for future management.
    Neuro Oncol. 2021 Oct 9. pii: 6385431. doi: 10.1093.
    PubMed    


  2. HOOGSTRATE Y, Ghisai SA, de Wit M, de Heer I, et al
    The EGFRvIII transcriptome in glioblastoma, a meta-omics analysis.
    Neuro Oncol. 2021 Oct 5. pii: 6381406. doi: 10.1093.
    PubMed     Abstract available


  3. STROWD RE
    Etched in Code: Revisiting glioma risk factors through the exome.
    Neuro Oncol. 2021 Oct 4. pii: 6380799. doi: 10.1093.
    PubMed    


  4. FRIEDMAN GK, Dhall G
    Potential Role of Carbon Ion Radiotherapy in Chromothripsis-induced Medulloblastoma and Other Malignancies.
    Neuro Oncol. 2021 Oct 4. pii: 6380754. doi: 10.1093.
    PubMed    


  5. WU J, Gupta R, Barreto J, Doo P, et al
    Tumor DNA requirements for accurate epigenetic-based classification of CNS neoplasia.
    Neuro Oncol. 2021;23:1798-1800.
    PubMed    


  6. PERTZ M, Schlegel U
    Tracking the neurobiology of cognitive dysfunction in primary CNS lymphoma?
    Neuro Oncol. 2021;23:1623-1624.
    PubMed    


  7. MILDE T, Rodriguez FJ, Barnholtz-Sloan JS, Patil N, et al
    Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas.
    Neuro Oncol. 2021;23:1634-1646.
    PubMed     Abstract available


  8. GENG H, Tsang M, Subbaraj L, Cleveland J, et al
    Tumor metabolism and neurocognition in CNS lymphoma.
    Neuro Oncol. 2021;23:1668-1679.
    PubMed     Abstract available


    September 2021
  9. DEL BENE M, Osti D, Faletti S, Beznousenko GV, et al
    Extracellular vesicles: the key for precision medicine in glioblastoma.
    Neuro Oncol. 2021 Sep 28. pii: 6377304. doi: 10.1093.
    PubMed     Abstract available


  10. RAO R, Han R, Ogurek S, Xue C, et al
    Glioblastoma Genetic Drivers Dictate the Function of Tumor-Associated Macrophages/Microglia and Responses to CSF1R Inhibition.
    Neuro Oncol. 2021 Sep 25. pii: 6375369. doi: 10.1093.
    PubMed     Abstract available


  11. PENG J, Kim DD, Patel JB, Zeng X, et al
    Corrigendum to: Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors.
    Neuro Oncol. 2021 Sep 22. pii: 6374130. doi: 10.1093.
    PubMed    


  12. JOSEPH JV, Magaut CR, Storevik S, Geraldo LH, et al
    TGF- promotes microtube formation in glioblastoma through Thrombospondin 1.
    Neuro Oncol. 2021 Sep 20. pii: 6372853. doi: 10.1093.
    PubMed     Abstract available


  13. LUCAS CG, Mueller S, Reddy A, Taylor JW, et al
    Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy.
    Neuro Oncol. 2021 Sep 14. pii: 6370137. doi: 10.1093.
    PubMed    


  14. WANG W, He H, Marin-Ramos NI, Zeng S, et al
    Corrigendum to: Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
    Neuro Oncol. 2021 Sep 14. pii: 6370123. doi: 10.1093.
    PubMed    


  15. BORNHORST M
    New insights into low grade glioma tumor microenvironment for improved patient management.
    Neuro Oncol. 2021 Sep 13. pii: 6369407. doi: 10.1093.
    PubMed    


  16. ABOUNADER R, Schiff D
    The blood-brain barrier limits the therapeutic efficacy of antibody drug conjugates in glioblastoma.
    Neuro Oncol. 2021 Sep 13. pii: 6369406. doi: 10.1093.
    PubMed    


  17. ZHANG W, Talele S, Sarkaria JN, Elmquist WF, et al
    Changes in the vasculature of human brain tumors: Implications for treatment.
    Neuro Oncol. 2021 Sep 13. pii: 6369378. doi: 10.1093.
    PubMed    


  18. IJARE OB, Hambarde S, Brasil da Costa FH, Lopez S, et al
    Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas.
    Neuro Oncol. 2021 Sep 13. pii: 6369334. doi: 10.1093.
    PubMed     Abstract available


  19. MAROSI C
    Will mastering ferroptosis allow treating refractory meningiomas?
    Neuro Oncol. 2021 Sep 13. pii: 6369228. doi: 10.1093.
    PubMed    


  20. DRIVER J, Hoffman SE, Tavakol S, Woodward E, et al
    A Molecularly Integrated Grade for Meningioma.
    Neuro Oncol. 2021 Sep 11. pii: 6368844. doi: 10.1093.
    PubMed     Abstract available


  21. TOM MC, Kotecha R
    Beating a Benchmark: Boron Neutron Capture Therapy for Recurrent and Refractory Meningiomas.
    Neuro Oncol. 2021 Sep 11. pii: 6368846. doi: 10.1093.
    PubMed    


  22. IUS T, Ng S, Young JS, Tomasino B, et al
    The benefit of early surgery on overall survival in incidental low grade glioma patients: a multicenter study.
    Neuro Oncol. 2021 Sep 8. pii: 6366593. doi: 10.1093.
    PubMed     Abstract available


  23. SAUNDERS CN, Kinnersley B, Culliford R, Cornish AJ, et al
    Relationship between genetically determined telomere length and glioma risk.
    Neuro Oncol. 2021 Sep 3. pii: 6363706. doi: 10.1093.
    PubMed     Abstract available


  24. WANG D, Veo B, Pierce A, Fosmire S, et al
    A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
    Neuro Oncol. 2021 Sep 3. pii: 6363671. doi: 10.1093.
    PubMed     Abstract available


  25. BANDOPADHAYAY P, Chi SN
    The challenges in treating Embryonal Tumors with Multilayered Rosettes (ETMR) and other infant brain tumors.
    Neuro Oncol. 2021 Sep 3. pii: 6363655. doi: 10.1093.
    PubMed    


  26. AQUILANTI E, Kageler L, Wen PY, Meyerson M, et al
    Telomerase as a therapeutic target in glioblastoma.
    Neuro Oncol. 2021 Sep 2. pii: 6362724. doi: 10.1093.
    PubMed     Abstract available


  27. BRANDNER S, McAleenan A, Kelly C, Spiga F, et al
    MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
    Neuro Oncol. 2021;23:1457-1469.
    PubMed     Abstract available


  28. THACKER N, Bouffet E
    Posterior fossa syndrome-time to unmute the silence on cerebellar mutism.
    Neuro Oncol. 2021;23:1427-1428.
    PubMed    


  29. VON HOFF K, Haberler C, Schmitt-Hoffner F, Schepke E, et al
    Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study.
    Neuro Oncol. 2021;23:1597-1611.
    PubMed     Abstract available


  30. KHAN RB, Patay Z, Klimo P, Huang J, et al
    Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study.
    Neuro Oncol. 2021;23:1586-1596.
    PubMed     Abstract available


    August 2021
  31. CHUNG C, Brown PD, Wefel JS
    Short reply to "Proton therapy for newly diagnosed glioblastoma: More room for investigation" by R. Press et al.
    Neuro Oncol. 2021 Aug 28. pii: 6359127. doi: 10.1093.
    PubMed    


  32. PRESS RH, Chhabra AM, Choi JI, Hasan S, et al
    Proton therapy for newly diagnosed glioblastoma: more room for investigation.
    Neuro Oncol. 2021 Aug 28. pii: 6359128. doi: 10.1093.
    PubMed    


  33. CICONE F, Cascini GL, Minniti G
    Reply to: "Letter to the Editor: Assessment of imaging biomarkers in the follow-up of brain metastases after SRS".
    Neuro Oncol. 2021 Aug 24. pii: 6357080. doi: 10.1093.
    PubMed    


  34. DERKS SHAE, Jongen JLM, van den Bent MJ, van der Veldt AAM, et al
    Assessment of imaging biomarkers in the follow-up of brain metastases after SRS.
    Neuro Oncol. 2021 Aug 24. pii: 6357079. doi: 10.1093.
    PubMed    


  35. RONSLEY R, Bouffet E
    COVID-19 in pediatric cancer: Where are the brain tumors?
    Neuro Oncol. 2021 Aug 20. pii: 6355395. doi: 10.1093.
    PubMed    


  36. WANG GM, Cioffi G, Patil N, Waite KA, et al
    Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas.
    Neuro Oncol. 2021 Aug 13. pii: 6350590. doi: 10.1093.
    PubMed     Abstract available


  37. JO J, Donahue J, Sarai G, Petroni G, et al
    Management of Venous Thromboembolism in High-Grade Glioma: Does Low Molecular Weight Heparin Increase Intracranial Bleeding Risk?
    Neuro Oncol. 2021 Aug 12. pii: 6348905. doi: 10.1093.
    PubMed     Abstract available


  38. YANG WC, Chen YF, Yang CC, Wu PF, et al
    Erratum to: Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial.
    Neuro Oncol. 2021 Aug 7. pii: 6345198. doi: 10.1093.
    PubMed    


  39. LAMBA N, Aizer AA
    The evolving role of systemic therapy and local, brain-directed treatment in patients with melanoma and brain metastases.
    Neuro Oncol. 2021 Aug 5. pii: 6341089. doi: 10.1093.
    PubMed    


  40. WINKLER F
    Silencing glioblastoma networks to make temozolomide more effective.
    Neuro Oncol. 2021 Aug 4. pii: 6339977. doi: 10.1093.
    PubMed    


  41. SU JM, Kilburn LB, Mansur DB, Krailo M, et al
    Phase 1/2 Trial of Vorinostat and Radiation and Maintenance Vorinostat in Children with Diffuse Intrinsic Pontine Glioma: A Children's Oncology Group Report.
    Neuro Oncol. 2021 Aug 4. pii: 6339987. doi: 10.1093.
    PubMed     Abstract available


  42. HUANG H, Georganaki M, Conze LL, Lavina B, et al
    ELTD1-deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.
    Neuro Oncol. 2021 Aug 4. pii: 6339962. doi: 10.1093.
    PubMed     Abstract available


  43. WEN PY, Packer RJ
    The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications.
    Neuro Oncol. 2021;23:1215-1217.
    PubMed    


  44. LOUIS DN, Perry A, Wesseling P, Brat DJ, et al
    The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
    Neuro Oncol. 2021;23:1231-1251.
    PubMed     Abstract available


  45. CORREA DD
    Neurocognitive functions in primary CNS lymphoma.
    Neuro Oncol. 2021;23:1220-1221.
    PubMed    


  46. MOSELLA MS, Sabedot TS, Silva TC, Malta TM, et al
    DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features.
    Neuro Oncol. 2021;23:1292-1303.
    PubMed     Abstract available


  47. VAN DER MEULEN M, Dirven L, Habets EJJ, Bakunina K, et al
    Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial.
    Neuro Oncol. 2021;23:1315-1326.
    PubMed     Abstract available


    July 2021
  48. MUNOZ PINTO MF, Campbell SJ, Simoglou Karali C, Johanssen VA, et al
    Selective blood-brain barrier permeabilisation of brain metastases by a type-1 receptor selective tumour necrosis factor mutein.
    Neuro Oncol. 2021 Jul 23. pii: 6326734. doi: 10.1093.
    PubMed     Abstract available


  49. RICHARDSON S, Hill RM, Kui C, Lindsey JC, et al
    Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse.
    Neuro Oncol. 2021 Jul 17. pii: 6323243. doi: 10.1093.
    PubMed     Abstract available


  50. SHIH HA
    An early foray with targeted therapy and inspiring novel approaches to combat adult medulloblastoma.
    Neuro Oncol. 2021 Jul 16. pii: 6323026. doi: 10.1093.
    PubMed    


  51. HULSBERGEN AFC, Abunimer AM, Ida F, Kavouridis VK, et al
    Neurosurgical resection for locally recurrent brain metastasis.
    Neuro Oncol. 2021 Jul 16. pii: 6322695. doi: 10.1093.
    PubMed     Abstract available


  52. SHARMA P, Xu J, Williams K, Easley M, et al
    Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
    Neuro Oncol. 2021 Jul 14. pii: 6321319. doi: 10.1093.
    PubMed     Abstract available


  53. LUDWIG N, Rao A, Sandlesh P, Yerneni SS, et al
    Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles.
    Neuro Oncol. 2021 Jul 13. pii: 6320007. doi: 10.1093.
    PubMed     Abstract available


  54. RAMASWAMY V, Bartels U
    Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel?
    Neuro Oncol. 2021 Jul 12. pii: 6319139. doi: 10.1093.
    PubMed    


  55. BALANA C, Sun C, Vaz MA, Esteve A, et al
    Reply to: Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
    Neuro Oncol. 2021 Jul 9. pii: 6318238. doi: 10.1093.
    PubMed    


  56. TERABE M, Wu J
    Rethinking Immunotherapy in Meningiomas.
    Neuro Oncol. 2021 Jul 9. pii: 6318447. doi: 10.1093.
    PubMed    


  57. ZHAO B, Ma W
    Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
    Neuro Oncol. 2021 Jul 9. pii: 6318242. doi: 10.1093.
    PubMed    


  58. BAGLEY SJ, Kline CN
    Understanding the global impact of primary brain tumors: the untapped potential of population-based cancer registries.
    Neuro Oncol. 2021 Jul 9. pii: 6318451. doi: 10.1093.
    PubMed    


  59. LUKAS RV
    Essential Oils for Blood-Brain Barrier Disruption: Preclinical Studies of NEO100 in Breast Cancer Brain Metastases.
    Neuro Oncol. 2021 Jul 9. pii: 6318449. doi: 10.1093.
    PubMed    


  60. ALHALABI OT, Fletcher MNC, Hielscher T, Kessler T, et al
    A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma.
    Neuro Oncol. 2021 Jul 7. pii: 6316731. doi: 10.1093.
    PubMed     Abstract available


  61. TONOGAI EJ, Huang S, Botham RC, Berry MR, et al
    Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
    Neuro Oncol. 2021 Jul 3. pii: 6314291. doi: 10.1093.
    PubMed     Abstract available


  62. TEHRANIAN C, Fankhauser L, Harter PN, Ratcliffe CDH, et al
    The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis.
    Neuro Oncol. 2021 Jul 3. pii: 6314211. doi: 10.1093.
    PubMed     Abstract available


  63. PETRIDIS PD, Horenstein C, Pereira B, Wu P, et al
    BOLD Asynchrony Elucidates Tumor Burden in IDH-Mutated Gliomas.
    Neuro Oncol. 2021 Jul 2. pii: 6313213. doi: 10.1093.
    PubMed     Abstract available


  64. YAMAZAKI S, Ohka F, Hirano M, Shiraki Y, et al
    Newly Established Patient-derived Organoid Model of Intracranial Meningioma.
    Neuro Oncol. 2021 Jul 2. pii: 6313216. doi: 10.1093.
    PubMed     Abstract available


  65. D'ALESSANDRIS QG, Della Pepa GM, Noya C, Olivi A, et al
    Mesenchymal stem cells: are they the good or the bad?
    Neuro Oncol. 2021;23:1203-1204.
    PubMed    


  66. DANKNER M, Maritan SM
    The relevance of surgical status in nodular leptomeningeal metastasis patient outcomes.
    Neuro Oncol. 2021;23:1207.
    PubMed    


  67. LE RHUN E, Devos P, Weller J, Seystahl K, et al
    Prognostic factors in leptomeningeal metastases.
    Neuro Oncol. 2021;23:1208-1209.
    PubMed    


  68. BARAJAS RF, Politi LS, Anzalone N, Schoder H, et al
    Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).
    Neuro Oncol. 2021;23:1056-1071.
    PubMed     Abstract available


  69. LE RHUN E, Devos P, Weller J, Seystahl K, et al
    Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors.
    Neuro Oncol. 2021;23:1100-1112.
    PubMed     Abstract available


  70. FORDE C, King AT, Rutherford SA, Hammerbeck-Ward C, et al
    Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution.
    Neuro Oncol. 2021;23:1113-1124.
    PubMed     Abstract available


    June 2021
  71. GOLDBRUNNER R, Stavrinou P, Jenkinson MD, Sahm F, et al
    EANO guideline on the diagnosis and management of meningiomas.
    Neuro Oncol. 2021 Jun 28. pii: 6310843. doi: 10.1093.
    PubMed     Abstract available


  72. WALBERT T, Harrison RA, Schiff D, Avila EK, et al
    SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.
    Neuro Oncol. 2021 Jun 26. pii: 6310125. doi: 10.1093.
    PubMed     Abstract available


  73. PENG J, Kim DD, Patel JB, Zeng X, et al
    Deep Learning-Based Automatic Tumor Burden Assessment of Pediatric High-Grade Gliomas, Medulloblastomas, and Other Leptomeningeal Seeding Tumors.
    Neuro Oncol. 2021 Jun 26. pii: 6310123. doi: 10.1093.
    PubMed     Abstract available


  74. WIRSCHING HG, Steiner L, Becker D, Regli L, et al
    Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression.
    Neuro Oncol. 2021 Jun 19. pii: 6305986. doi: 10.1093.
    PubMed    


  75. JOHNSON KC, Verhaak RGW
    Serum cell-free DNA epigenetic biomarkers aid glioma diagnostics and monitoring.
    Neuro Oncol. 2021 Jun 17. pii: 6302547. doi: 10.1093.
    PubMed    


  76. HAU P
    Dissecting adult SHH-activated medulloblastoma - molecularly defined tumor subsets reveal new prognostic biomarkers.
    Neuro Oncol. 2021 Jun 17. pii: 6302543. doi: 10.1093.
    PubMed    


  77. SHAH AH, Gilbert M, Ivan ME, Komotar RJ, et al
    The role of human endogenous retroviruses in gliomas: from etiological perspectives and therapeutic implications.
    Neuro Oncol. 2021 Jun 12. pii: 6297568. doi: 10.1093.
    PubMed     Abstract available


  78. ERKER C, Lane A, Chaney B, Leary S, et al
    Characteristics of Patients >/= 10 Years of Age with Diffuse Intrinsic Pontine Glioma: A Report from the International DIPG Registry.
    Neuro Oncol. 2021 Jun 11. pii: 6296498. doi: 10.1093.
    PubMed     Abstract available


  79. SHEEHAN J, Pikis S, Islim A, Chen CJ, et al
    An International Multicenter Matched Cohort Analysis of Incidental Meningioma Progression During Active Surveillance or After Stereotactic Radiosurgery: The IMPASSE Study.
    Neuro Oncol. 2021 Jun 9. pii: 6295369. doi: 10.1093.
    PubMed     Abstract available


  80. KOTECHA R, Aboian M, Nabavizadeh SA, Parent EE, et al
    Letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation.
    Neuro Oncol. 2021 Jun 3. pii: 6291736. doi: 10.1093.
    PubMed    


  81. GALLDIKS N, Niyazi M, Tonn JC, Langen KJ, et al
    Reply to the letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation.
    Neuro Oncol. 2021 Jun 3. pii: 6291737. doi: 10.1093.
    PubMed    


  82. RIEMONDY KA, Venkataraman S, Willard N, Nellan A, et al
    Neoplastic and immune single cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma.
    Neuro Oncol. 2021 Jun 2. pii: 6291352. doi: 10.1093.
    PubMed     Abstract available


  83. RITZMANN TA, Kilday JP, Grundy RG
    Pediatric ependymomas: destined to recur?
    Neuro Oncol. 2021;23:874-876.
    PubMed    


  84. POON MTC, Brennan PM, Jin K, Sudlow CLM, et al
    Might changes in diagnostic practice explain increasing incidence of brain and central nervous system tumors? A population-based study in Wales (United Kingdom) and the United States.
    Neuro Oncol. 2021;23:979-989.
    PubMed     Abstract available


  85. ADOLPH JE, Fleischhack G, Mikasch R, Zeller J, et al
    Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study.
    Neuro Oncol. 2021;23:1012-1023.
    PubMed     Abstract available


    May 2021
  86. PHILLIPS LM, Li S, Gumin J, Daou M, et al
    An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
    Neuro Oncol. 2021 May 31. pii: 6290257. doi: 10.1093.
    PubMed     Abstract available


  87. MARIN BM, Porath KA, Jain S, Kim M, et al
    Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
    Neuro Oncol. 2021 May 29. pii: 6288409. doi: 10.1093.
    PubMed     Abstract available


  88. SCOCCIANTI S, Olmetto E, Pinzi V, Osti MF, et al
    Immunotherapy in association with stereotactic radiotherapy for Non-Small Cell Lung Cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO.
    Neuro Oncol. 2021 May 29. pii: 6288399. doi: 10.1093.
    PubMed     Abstract available


  89. VERBURG N, Barthel FP, Anderson KJ, Johnson KC, et al
    Spatial concordance of DNA methylation classification in diffuse glioma.
    Neuro Oncol. 2021 May 28. pii: 6287958. doi: 10.1093.
    PubMed     Abstract available


  90. SIMOVIC M, Bolkestein M, Moustafa M, Wong JKL, et al
    Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model.
    Neuro Oncol. 2021 May 28. pii: 6287957. doi: 10.1093.
    PubMed     Abstract available


  91. DE ANDRADE COSTA A, Chatterjee J, Cobb O, Sanapala S, et al
    RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth.
    Neuro Oncol. 2021 May 27. pii: 6286081. doi: 10.1093.
    PubMed     Abstract available


  92. LI Y, Wang X, Qi S, Gao L, et al
    Spliceosome-regulated RSRP1-dependent NF-kappaB activation promotes the glioblastoma mesenchymal phenotype.
    Neuro Oncol. 2021 May 27. pii: 6286882. doi: 10.1093.
    PubMed     Abstract available


  93. LAPERRIERE NJ
    Protons for the Management of Adult Patients with Glioblastoma.
    Neuro Oncol. 2021 May 24. pii: 6283746. doi: 10.1093.
    PubMed    


  94. MENDOZA TR
    Especially for neuro-oncologists - minimally important differences for the EORTC QLQ-C30 in glioma patients.
    Neuro Oncol. 2021 May 24. pii: 6283743. doi: 10.1093.
    PubMed    


  95. CHONGSATHIDKIET P, Fecci PE
    Cold-inducible RNA-binding protein (CIRBP) as a biomarker to predict recurrence of brain metastases.
    Neuro Oncol. 2021 May 24. pii: 6283744. doi: 10.1093.
    PubMed    


  96. BI WL, Nayak L, Meredith DM, Driver J, et al
    Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results.
    Neuro Oncol. 2021 May 20. pii: 6279078. doi: 10.1093.
    PubMed     Abstract available


  97. GUSYATINER O, Bady P, Pham MDT, Lei Y, et al
    BET inhibitors repress expression of Interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.
    Neuro Oncol. 2021 May 14. pii: 6275457. doi: 10.1093.
    PubMed     Abstract available


  98. SIM HW, McDonald KL, Lwin Z, Barnes EH, et al
    A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
    Neuro Oncol. 2021 May 13. pii: 6275307. doi: 10.1093.
    PubMed     Abstract available


  99. DAHL NA, Vibhakar R
    Converging evidence for inhibition of transcriptional control in high-grade gliomas.
    Neuro Oncol. 2021 May 13. pii: 6275360. doi: 10.1093.
    PubMed    


  100. TAKAI S, Wanibuchi M, Kawabata S, Takeuchi K, et al
    Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up.
    Neuro Oncol. 2021 May 13. pii: 6275296. doi: 10.1093.
    PubMed     Abstract available


  101. BAO Z, Hua L, Ye Y, Wang D, et al
    MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma.
    Neuro Oncol. 2021 May 13. pii: 6275374. doi: 10.1093.
    PubMed     Abstract available


  102. WANG Z, Gao L, Wang Y, Chang M, et al
    Validation of the prognostic value of 9-gene ATE score for IDH wild-type glioblastoma.
    Neuro Oncol. 2021 May 13. pii: 6275034. doi: 10.1093.
    PubMed    


  103. NASSIRI F, Wang JZ, Singh O, Karimi S, et al
    Loss of H3K27me3 in meningiomas.
    Neuro Oncol. 2021 May 10. pii: 6273127. doi: 10.1093.
    PubMed     Abstract available


  104. FELKER J, Agnihotri S
    Not all mouse blood-brain barriers are created equal.
    Neuro Oncol. 2021;23:705-706.
    PubMed    


  105. SO J, Mamatjan Y, Zadeh G, Aldape K, et al
    Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis.
    Neuro Oncol. 2021;23:795-802.
    PubMed     Abstract available


  106. MASSIMINO M, Barretta F, Modena P, Witt H, et al
    Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up.
    Neuro Oncol. 2021;23:848-857.
    PubMed     Abstract available


  107. CLAUS EB, Cannataro VL, Gaffney SG, Townsend JP, et al
    Environmental and sex-specific molecular signatures of glioma causation.
    Neuro Oncol. 2021 May 4. pii: 6263733. doi: 10.1093.
    PubMed     Abstract available


    April 2021
  108. BRANDNER S, McAleenan A, Kelly C, Spiga F, et al
    MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Review.
    Neuro Oncol. 2021 Apr 30. pii: 6263562. doi: 10.1093.
    PubMed     Abstract available


  109. YEUNG J, Yaghoobi V, Miyagishima D, Vesely MD, et al
    Targeting the CSF1/CSF1R Axis is a Potential Treatment Strategy for Malignant Meningiomas.
    Neuro Oncol. 2021 Apr 29. pii: 6259024. doi: 10.1093.
    PubMed     Abstract available


  110. TESILEANU CMS, van den Bent MJ, Sanson M, Wick W, et al
    Prognostic significance of genome-wide DNA methylation profiles within the randomised, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
    Neuro Oncol. 2021 Apr 29. pii: 6259004. doi: 10.1093.
    PubMed     Abstract available


  111. LAMBA N, Wen PY, Aizer AA
    Epidemiology of Brain Metastases and Leptomeningeal Disease.
    Neuro Oncol. 2021 Apr 28. pii: 6256866. doi: 10.1093.
    PubMed     Abstract available


  112. STROTHER D, Lafay-Cousin L
    Adjuvant therapy for high risk medulloblastoma: More is better?
    Neuro Oncol. 2021 Apr 27. pii: 6254485. doi: 10.1093.
    PubMed    


  113. MARINELLI JP, Carlson ML
    Potential for selection bias surrounding reporting of benign brain tumors in the United States.
    Neuro Oncol. 2021 Apr 26. pii: 6253739. doi: 10.1093.
    PubMed    


  114. TAWBI HA, Forsyth PA, Hodi FS, Lao CD, et al
    Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204).
    Neuro Oncol. 2021 Apr 21. pii: 6242717. doi: 10.1093.
    PubMed     Abstract available


  115. NICLOU SP, Golebiewska A
    Turning strength into weakness: protein degradation and autophagy as therapeutic targets in Glioblastoma?
    Neuro Oncol. 2021 Apr 17. pii: 6231737. doi: 10.1093.
    PubMed    


  116. SCHNEIDER M, Vollmer L, Potthoff AL, Ravi VM, et al
    Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma.
    Neuro Oncol. 2021 Apr 17. pii: 6231712. doi: 10.1093.
    PubMed     Abstract available


  117. VISWANATH P, Batsios G, Ayyappan V, Taglang C, et al
    Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas.
    Neuro Oncol. 2021 Apr 17. pii: 6231711. doi: 10.1093.
    PubMed     Abstract available


  118. VOLMAR MNM, Cheng J, Alenezi H, Richter S, et al
    Cannabidiol converts NFkappaB into a tumor suppressor in glioblastoma with defined antioxidative properties.
    Neuro Oncol. 2021 Apr 17. pii: 6231710. doi: 10.1093.
    PubMed     Abstract available


  119. KATSUSHIMA K, Lee B, Kunhiraman H, Zhong C, et al
    The long noncoding RNA lnc-HLX-2-7 is oncogenic in Group 3 medulloblastomas.
    Neuro Oncol. 2021;23:572-585.
    PubMed     Abstract available


  120. THOMAS C, Soschinski P, Zwaig M, Oikonomopoulos S, et al
    The genetic landscape of choroid plexus tumors in children and adults.
    Neuro Oncol. 2021;23:650-660.
    PubMed     Abstract available


  121. WANIS HA, Moller H, Ashkan K, Davies EA, et al
    The incidence of major subtypes of primary brain tumours in adults in England 1995-2017.
    Neuro Oncol. 2021 Apr 9. pii: 6218679. doi: 10.1093.
    PubMed     Abstract available


  122. HORBINSKI C, McCortney K, Stupp R
    MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas.
    Neuro Oncol. 2021 Apr 8. pii: 6217333. doi: 10.1093.
    PubMed    


  123. MUKHERJEE S, Schiltz G, Clutter M, Mishra R, et al
    Erratum to: DDIS-27. TARGETING ATP DOCKING AND P35/P25 BINDING OF CDK5 IN GLIOMA STEM CELLS USING SYNTHETIC INHIBITORS.
    Neuro Oncol. 2021 Apr 7. pii: 6214067. doi: 10.1093.
    PubMed    


  124. MUKHERJEE S, Olson C, Dundar B, Sharma N, et al
    Erratum to: STEM-19. RESISTANCE IS FUTILE: UNDERSTANDING AND TARGETING THE CDK5-CREB1-MCL1 AXIS TO PREVENT RADIATION RESISTANCE IN GLIOMA STEM CELLS.
    Neuro Oncol. 2021 Apr 7. pii: 6214066. doi: 10.1093.
    PubMed    


  125. FRAPPAZ D, Barritault M, Montane L, Laigle-Donadey F, et al
    MEVITEM - A Phase I/II of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
    Neuro Oncol. 2021 Apr 7. pii: 6213882. doi: 10.1093.
    PubMed     Abstract available


  126. YU Y, Villanueva-Meyer J, Grimmer MR, Hilz S, et al
    Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
    Neuro Oncol. 2021 Apr 5. pii: 6211336. doi: 10.1093.
    PubMed     Abstract available


  127. SANTAGATA S, Ligon KL
    Prognostication for meningiomas: H3K27me3 to the rescue?
    Neuro Oncol. 2021 Apr 3. pii: 6209863. doi: 10.1093.
    PubMed    


  128. TSANG DS, Schulte F
    Beyond the brain: Socioeconomic status and race in pediatric brain tumor survivorship.
    Neuro Oncol. 2021 Apr 3. pii: 6209877. doi: 10.1093.
    PubMed    


  129. LEE EQ, Selig W, Meehan C, Bacha J, et al
    Report of National Brain Tumor Society Roundtable Workshop on Innovating Brain Tumor Clinical Trials: Building on Lessons Learned from COVID-19 Experience.
    Neuro Oncol. 2021 Apr 2. pii: 6209406. doi: 10.1093.
    PubMed     Abstract available


    March 2021
  130. PERKINS S, Acharya S
    Radiation therapy to the developing brain: advanced technology is ready for robust optimization parameters.
    Neuro Oncol. 2021;23:350-351.
    PubMed    


  131. LASSMAN AB, Cloughesy TF
    Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?
    Neuro Oncol. 2021;23:347-349.
    PubMed    


  132. KUMTHEKAR P, Dunbar EM, Peters KB, Brastianos PK, et al
    A broad perspective on evaluating bias in the neuro-oncology workplace.
    Neuro Oncol. 2021;23:498-499.
    PubMed    


  133. GILBERT MR, Yuan Y, Wu J, Mendoza T, et al
    A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
    Neuro Oncol. 2021;23:468-477.
    PubMed     Abstract available


  134. JAECKLE KA, Ballman KV, van den Bent M, Giannini C, et al
    CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
    Neuro Oncol. 2021;23:457-467.
    PubMed     Abstract available


  135. BOURDEAUT F
    Are B7-H3 CAR-T cells the future universal treatment for pediatric brain tumors?
    Neuro Oncol. 2021 Mar 23. pii: 6182498. doi: 10.1093.
    PubMed    


  136. LU SL, Xiao FR, Cheng JC, Yang WC, et al
    Randomized Multi-Reader Evaluation of Automated Detection and Segmentation of Brain Tumors in Stereotactic Radiosurgery with Deep Neural Networks.
    Neuro Oncol. 2021 Mar 23. pii: 6180141. doi: 10.1093.
    PubMed     Abstract available


  137. LATHIA JD
    Fountain of chaos: cerebrospinal fluid enhancement of cancer stem cells in glioblastoma.
    Neuro Oncol. 2021 Mar 22. pii: 6179836. doi: 10.1093.
    PubMed    


  138. NOBRE L, Ramaswamy V
    Medulloblastoma (cross)talk through extracellular vesicles.
    Neuro Oncol. 2021 Mar 22. pii: 6179837. doi: 10.1093.
    PubMed    


  139. OSTROM QT, Edelson J, Byun J, Han Y, et al
    Partitioned glioma heritability shows subtype-specific enrichment in immune cells.
    Neuro Oncol. 2021 Mar 20. pii: 6179266. doi: 10.1093.
    PubMed     Abstract available


  140. GIRARDI F, Rous B, Stiller CA, Gatta G, et al
    The histology of brain tumours for 67,331 children and 671,085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3).
    Neuro Oncol. 2021 Mar 19. pii: 6178525. doi: 10.1093.
    PubMed     Abstract available


  141. VERKOUTEREN BJA, Cosgun B, Vermeulen RJ, Reinders MGHC, et al
    Prevalence of medulloblastoma in basal cell nevus syndrome patients with a PTCH1 mutation.
    Neuro Oncol. 2021 Mar 17. pii: 6231902. doi: 10.1093.
    PubMed    


  142. TSIEN C
    Stereotactic radiation therapy with concurrent immunotherapy for recurrent glioblastoma-hope or hype?
    Neuro Oncol. 2021 Mar 12. pii: 6168946. doi: 10.1093.
    PubMed    


  143. WINKLER F
    In glioma, all endothelial cells are not created the same.
    Neuro Oncol. 2021 Mar 11. pii: 6168415. doi: 10.1093.
    PubMed    


  144. SAIT SF, Karajannis MA
    Pediatric spinal cord gliomas - low grade but high risk for recurrence: should we treat them differently from intracranial low-grade gliomas?
    Neuro Oncol. 2021 Mar 11. pii: 6168346. doi: 10.1093.
    PubMed    


  145. TRIFILETTI DM, Brown PD
    Cognitive outcomes in patients with low-grade glioma.
    Neuro Oncol. 2021 Mar 11. pii: 6168225. doi: 10.1093.
    PubMed    


  146. FONSECA A, Bouffet E
    Brainstem Gliomas... The Devil is in the Details.
    Neuro Oncol. 2021 Mar 11. pii: 6168340. doi: 10.1093.
    PubMed    


  147. BAUMERT BG, Pesce GA
    Elderly patients with brain metastases: new support for the balancing act in treatment decision making.
    Neuro Oncol. 2021 Mar 11. pii: 6168221. doi: 10.1093.
    PubMed    


  148. MENG Y, Pople CB, Suppiah S, Llinas M, et al
    MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors.
    Neuro Oncol. 2021 Mar 10. pii: 6167330. doi: 10.1093.
    PubMed     Abstract available


  149. LIM-FAT MJ, Maralani PJ
    Is there an optimal MRI surveillance schedule for patients with high grade glioma after standard of care therapy?
    Neuro Oncol. 2021 Mar 1. pii: 6155531. doi: 10.1093.
    PubMed    


  150. SPERDUTO PW, Lou E
    The Past, Current and Future Management of Brain Metastases in EGFR-Mutant Non-Small Cell Lung Cancer.
    Neuro Oncol. 2021 Mar 1. pii: 6155599. doi: 10.1093.
    PubMed    


    February 2021
  151. GIANNINI C, Giangaspero F
    TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH-wildtype glioblastoma?
    Neuro Oncol. 2021 Feb 28. pii: 6154503. doi: 10.1093.
    PubMed    


  152. WANG W, He H, Marin-Ramos NI, Zeng S, et al
    Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
    Neuro Oncol. 2021 Feb 28. pii: 6154448. doi: 10.1093.
    PubMed     Abstract available


  153. BROWN PD, Chung C, Liu DD, McAvoy S, et al
    A Prospective Phase II Randomized Trial of Proton Radiotherapy vs. Intensity Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma.
    Neuro Oncol. 2021 Feb 27. pii: 6154000. doi: 10.1093.
    PubMed     Abstract available


  154. JESSURUN CAC, Hulsbergen AFC, de Wit AE, Tewarie IA, et al
    The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis.
    Neuro Oncol. 2021 Feb 25. pii: 6150018. doi: 10.1093.
    PubMed     Abstract available


  155. FANGUSARO J, Onar-Thomas A, Poussaint TY, Wu S, et al
    A Phase 2 Trial of Selumetinib in Children with Recurrent Optic Pathway and Hypothalamic Low-Grade Glioma without NF1: A Pediatric Brain Tumor Consortium Study.
    Neuro Oncol. 2021 Feb 25. pii: 6149924. doi: 10.1093.
    PubMed     Abstract available


  156. TSCHERNICHOVSKY R, Katz LH, Derazne E, Berliner MB, et al
    Height in Adolescence as a Risk Factor for Glioma Subtypes: a Nationwide Retrospective Cohort Study of 2.2 Million Subjects.
    Neuro Oncol. 2021 Feb 25. pii: 6149925. doi: 10.1093.
    PubMed     Abstract available


  157. JAIN R, Chi AS
    Radiogenomics identifying important biological pathways in gliomas.
    Neuro Oncol. 2021;23:177-178.
    PubMed    


  158. ELLINGSON BM, Brown MS, Boxerman JL, Gerstner ER, et al
    Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.
    Neuro Oncol. 2021;23:189-198.
    PubMed     Abstract available


  159. KANAMORI M, Takami H, Yamaguchi S, Sasayama T, et al
    So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?
    Neuro Oncol. 2021;23:295-303.
    PubMed     Abstract available


  160. CANNON-ALBRIGHT LA, Farnham JM, Stevens J, Teerlink CC, et al
    Genome-wide analysis of high-risk primary brain cancer pedigrees identifies PDXDC1 as a candidate brain cancer predisposition gene.
    Neuro Oncol. 2021;23:277-283.
    PubMed     Abstract available


  161. MATHEN P, Smart DK
    Reimagining External Beam Radiotherapy for Glioblastoma: "Old Beam, New Trick".
    Neuro Oncol. 2021 Feb 22. pii: 6146614. doi: 10.1093.
    PubMed    


  162. KIM MM, Aryal MP, Sun Y, Parmar HA, et al
    Response assessment during chemoradiation using a hypercellular/hyperperfused imaging phenotype predicts survival in patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2021 Feb 18. pii: 6144576. doi: 10.1093.
    PubMed     Abstract available


  163. DIRVEN L, Musoro JZ, Coens C, Reijneveld JC, et al
    Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.
    Neuro Oncol. 2021 Feb 18. pii: 6142946. doi: 10.1093.
    PubMed     Abstract available


  164. KORSHUNOV A, Okonechnikov K, Stichel D, Ryzhova M, et al
    Integrated molecular analysis of adult Sonic Hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator.
    Neuro Oncol. 2021 Feb 16. pii: 6137557. doi: 10.1093.
    PubMed     Abstract available


  165. HUANG T, Cheng SY
    Targeting phospholipid metabolism for glioblastoma therapy.
    Neuro Oncol. 2021 Feb 9. pii: 6131652. doi: 10.1093.
    PubMed    


  166. SCHAFFENRATH J, Wyss T, He L, Rushing EJ, et al
    Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling.
    Neuro Oncol. 2021 Feb 9. pii: 6131739. doi: 10.1093.
    PubMed     Abstract available


  167. SABEDOT T, Malta T, Snyder J, Nelson K, et al
    A serum-based DNA methylation assay provides accurate detection of glioma.
    Neuro Oncol. 2021 Feb 9. pii: 6131768. doi: 10.1093.
    PubMed     Abstract available


  168. GRAILLON T, Ferrer L, Siffre J, Sanson M, et al
    Role of 3-D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.
    Neuro Oncol. 2021 Feb 8. pii: 6131353. doi: 10.1093.
    PubMed     Abstract available


  169. GUO X, Wang S, Wang Y, Ma W, et al
    Anti-PD-1 plus anti-VEGF therapy in multiple intracranial metastases of a hypermutated, IDH wild-type glioblastoma.
    Neuro Oncol. 2021 Feb 8. pii: 6131355. doi: 10.1093.
    PubMed    


  170. YAMAMOTO M, Sanomachi T, Suzuki S, Uchida H, et al
    Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.
    Neuro Oncol. 2021 Feb 8. pii: 6131352. doi: 10.1093.
    PubMed     Abstract available


  171. OTANI Y, Sur H, Rachaiah G, Namagiri S, et al
    Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
    Neuro Oncol. 2021 Feb 8. pii: 6131351. doi: 10.1093.
    PubMed     Abstract available


  172. TORRES VA, Ashford JM, Wright E, Xu J, et al
    The Impact of Socioeconomic Status (SES) on Cognitive Outcomes Following Radiotherapy for Pediatric Brain Tumors: A Prospective, Longitudinal Trial.
    Neuro Oncol. 2021 Feb 5. pii: 6128895. doi: 10.1093.
    PubMed     Abstract available


  173. LIAO Y, Luo Z, Deng Y, Zhang F, et al
    OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes.
    Neuro Oncol. 2021 Feb 4. pii: 6128721. doi: 10.1093.
    PubMed     Abstract available


  174. GALLDIKS N, Niyazi M, Grosu AL, Kocher M, et al
    Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group.
    Neuro Oncol. 2021 Feb 4. pii: 6128548. doi: 10.1093.
    PubMed     Abstract available


    January 2021
  175. WEFEL JS, Armstrong TS, Pugh SL, Gilbert MR, et al
    Neurocognitive, Symptom, and Health- Related Quality of Life Outcomes of a Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma (NRG/RTOG 0825).
    Neuro Oncol. 2021 Jan 30. pii: 6124000. doi: 10.1093.
    PubMed     Abstract available


  176. YANG TJ, Wijetunga NA, Yamada J, Wolden S, et al
    Clinical trial of proton craniospinal irradiation for leptomeningeal metastases.
    Neuro Oncol. 2021;23:134-143.
    PubMed     Abstract available


  177. NARITA Y, Nagane M, Mishima K, Terui Y, et al
    Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
    Neuro Oncol. 2021;23:122-133.
    PubMed     Abstract available


  178. MAIRE CL, Fuh MM, Kaulich K, Fita KD, et al
    Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification.
    Neuro Oncol. 2021 Jan 28. pii: 6122789. doi: 10.1093.
    PubMed     Abstract available


  179. GERRITSEN JKW, Vincent AJPE, De Vleeschouwer S
    Maximizing extent of resection while minimizing the risk of neurological morbidity in glioma patients: a novel grading scale to translate these surgical goals into a merged onco-functional clinical outcome.
    Neuro Oncol. 2021 Jan 20. pii: 6104892. doi: 10.1093.
    PubMed    


  180. VARGAS LOPEZ AJ
    Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
    Neuro Oncol. 2021 Jan 20. pii: 6104916. doi: 10.1093.
    PubMed    


  181. DIAMANDIS P
    De-coding group 3 medulloblastoma biology with non-coding RNA.
    Neuro Oncol. 2021 Jan 20. pii: 6104902. doi: 10.1093.
    PubMed    


  182. KATAGI H, Takata N, Aoi Y, Zhang Y, et al
    Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
    Neuro Oncol. 2021 Jan 20. pii: 6104638. doi: 10.1093.
    PubMed     Abstract available


  183. WEN PY, Weller M, Chiocca EA, Lim M, et al
    Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez.
    Neuro Oncol. 2021 Jan 20. pii: 6104896. doi: 10.1093.
    PubMed    


  184. FULTS DW
    Stemming the growth of pediatric gliomas through histone modification.
    Neuro Oncol. 2021 Jan 20. pii: 6104497. doi: 10.1093.
    PubMed    


  185. DMYTRIW AA, Huang RY
    In search of predictive and response markers in antiangiogenic therapy of glioblastoma.
    Neuro Oncol. 2021 Jan 20. pii: 6104491. doi: 10.1093.
    PubMed    


  186. DANKNER M, Caron M, Al-Saadi T, Yu W, et al
    Invasive growth associated with Cold-Inducible RNA-Binding Protein expression drives recurrence of surgically resected brain metastases.
    Neuro Oncol. 2021 Jan 12. pii: 6089125. doi: 10.1093.
    PubMed     Abstract available


  187. WU S, Li X, Gao F, de Groot JF, et al
    PARP mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
    Neuro Oncol. 2021 Jan 12. pii: 6089123. doi: 10.1093.
    PubMed     Abstract available


  188. BENITEZ JA, Finlay D, Castanza A, Parisian AD, et al
    Pten Deficiency Leads To Proteasome Addiction, A Novel Vulnerability In Glioblastoma.
    Neuro Oncol. 2021 Jan 11. pii: 6081306. doi: 10.1093.
    PubMed     Abstract available


  189. GUTMAN DC, Young RJ
    IDH glioma radiogenomics in the era of deep learning.
    Neuro Oncol. 2021 Jan 8. pii: 6068851. doi: 10.1093.
    PubMed    


  190. SNUDERL M
    Molecular classification and deconvolution of the immune microenvironment in glioblastoma.
    Neuro Oncol. 2021 Jan 4. pii: 6062458. doi: 10.1093.
    PubMed    


  191. SHOFUDA T, Kanemura Y
    HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?
    Neuro Oncol. 2021 Jan 4. pii: 6062389. doi: 10.1093.
    PubMed    


    December 2020
  192. SHAHZAD U, Taccone MS, Kumar SA, Okura H, et al
    Modeling human brain tumours in flies, worms, and zebrafish: From proof of principle to novel therapeutic targets.
    Neuro Oncol. 2020 Dec 30. pii: 6055605. doi: 10.1093.
    PubMed     Abstract available


  193. DUFOUR C, Foulon S, Geoffray A, Masliah-Planchon J, et al
    Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase 2 trial PNET HR+5.
    Neuro Oncol. 2020 Dec 30. pii: 6055191. doi: 10.1093.
    PubMed     Abstract available


  194. CHUNTOVA P, Chow F, Watchmaker P, Galvez M, et al
    Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology.
    Neuro Oncol. 2020 Dec 24. pii: 6047273. doi: 10.1093.
    PubMed     Abstract available


  195. BEHLING F, Fodi C, Gepfner-Tuma I, Kaltenbach K, et al
    H3K27me3 loss indicates an increased risk of recurrence in the Tubingen meningioma cohort.
    Neuro Oncol. 2020 Dec 24. pii: 6046432. doi: 10.1093.
    PubMed     Abstract available


  196. KUKSIS M, Gao Y, Tran W, Hoey C, et al
    The Incidence of Brain Metastases Among Patients with Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
    Neuro Oncol. 2020 Dec 23. pii: 6046194. doi: 10.1093.
    PubMed     Abstract available


  197. CARLSON JC, Cantu-Gutierrez M, Lozzi B, Huang-Hobbs E, et al
    Identification of diverse tumor endothelial cell populations in malignant glioma.
    Neuro Oncol. 2020 Dec 23. pii: 6046199. doi: 10.1093.
    PubMed     Abstract available


  198. PATIL N, Kelly ME, Yeboa DN, Buerki RA, et al
    Epidemiology of Brainstem High-Grade Gliomas in Children and Adolescents in the United States, 2000-2017.
    Neuro Oncol. 2020 Dec 21. pii: 6042829. doi: 10.1093.
    PubMed     Abstract available


  199. PERWEIN T, Benesch M, Kandels D, Pietsch T, et al
    High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): Management strategies and results from the German LGG study group.
    Neuro Oncol. 2020 Dec 21. pii: 6042812. doi: 10.1093.
    PubMed     Abstract available


  200. BERNHARDT D, Combs SE
    Reply to: "Call of duty: neuro-oncology outpatient management during the COVID-19 pandemic in Milan, Italy".
    Neuro Oncol. 2020;22:1893.
    PubMed    


  201. YANG Z, Zhang Y, Li R, Yisikandaer A, et al
    Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial.
    Neuro Oncol. 2020 Dec 17. pii: 6040795. doi: 10.1093.
    PubMed     Abstract available


  202. LIU Y, Li Z, Zhang M, Zhou H, et al
    Rolling-translated EGFR Variants Sustain EGFR Signaling and Promote Glioblastoma Tumorigenicity.
    Neuro Oncol. 2020 Dec 16. pii: 6039055. doi: 10.1093.
    PubMed     Abstract available


  203. HAYDAR D, Houke H, Chiang J, Yi Z, et al
    Cell surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
    Neuro Oncol. 2020 Dec 15. pii: 6035165. doi: 10.1093.
    PubMed     Abstract available


  204. XIE R, Kessler T, Grosch J, Hai L, et al
    Tumor cell network integration in glioma represents a stemness feature.
    Neuro Oncol. 2020 Dec 15. pii: 6035154. doi: 10.1093.
    PubMed     Abstract available


  205. PUDUVALLI VK
    Demystifying Demethylator Sensitivity in Gliomas: Role for TERT and DNMT1.
    Neuro Oncol. 2020 Dec 2. pii: 6017324. doi: 10.1093.
    PubMed    


  206. HUANG J, Mehta M
    Can proton therapy reduce radiation-related lymphopenia in glioblastoma?
    Neuro Oncol. 2020 Dec 2. pii: 6017294. doi: 10.1093.
    PubMed    


  207. GENOVESI LA, Puttick S, Millar A, Kojic M, et al
    Patient derived orthotopic xenograft models of Medulloblastoma lack a functional blood brain barrier.
    Neuro Oncol. 2020 Dec 1. pii: 6015057. doi: 10.1093.
    PubMed     Abstract available


  208. YUAN M, White D, Resar L, Bar E, et al
    Conditional reprograming culture conditions facilitate growth of lower grade glioma models.
    Neuro Oncol. 2020 Dec 1. pii: 6015051. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  209. KHASRAW M, Walsh KM, Heimberger AB, Ashley DM, et al
    What is the Burden of Proof for Tumor Mutational Burden in gliomas?
    Neuro Oncol. 2020 Nov 30. pii: 6012765. doi: 10.1093.
    PubMed     Abstract available


  210. LARA-VELAZQUEZ M, Zarco N, Carrano A, Phillipps J, et al
    Alpha 1-antichymotrypsin contributes to stem cell characteristics and enhances tumorigenicity of Glioblastoma.
    Neuro Oncol. 2020 Nov 29. pii: 6010432. doi: 10.1093.
    PubMed     Abstract available


  211. ZHENG ZQ, Chen JT, Zheng MC, Yang LJ, et al
    Nestin +/CD31 + Cells in the Hypoxic Perivascular Niche Regulate Glioblastoma Chemoresistance by Upregulating JAG1 and DLL4.
    Neuro Oncol. 2020 Nov 29. pii: 6010441. doi: 10.1093.
    PubMed     Abstract available


  212. NIU X, Yang Y, Zhou X, Zhang H, et al
    A prognostic nomogram for patients with newly diagnosed adult thalamic glioma in a surgical cohort.
    Neuro Oncol. 2020 Nov 27. pii: 6007003. doi: 10.1093.
    PubMed    


  213. KAUFMANN TJ, Smits M, Boxerman J, Huang R, et al
    Response to Letter to Editor.
    Neuro Oncol. 2020;22:1706-1707.
    PubMed    


  214. LE RHUN E, Weller M, Le Deley MC
    DEPOSEIN-how meaningful was the benefit from intrathecal chemotherapy?
    Neuro Oncol. 2020;22:1710-1711.
    PubMed    


  215. VOGELBAUM MA, Krivosheya D, Borghei-Razavi H, Sanai N, et al
    Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review.
    Neuro Oncol. 2020;22:1568-1579.
    PubMed     Abstract available


  216. OERMANN EK, Germano IM
    In the pursuit of glioma diagnosis - the challenges and opportunities of deep neural network augmented analyses.
    Neuro Oncol. 2020 Nov 12. pii: 5979500. doi: 10.1093.
    PubMed    


  217. ALBERT TK, Interlandi M, Sill M, Graf M, et al
    An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastoma.
    Neuro Oncol. 2020 Nov 11. pii: 5974128. doi: 10.1093.
    PubMed     Abstract available


  218. MITCHELL K, Troike K, Silver DJ, Lathia JD, et al
    The evolution of the cancer stem cell state in glioblastoma - emerging insights into the next-generation of functional interactions.
    Neuro Oncol. 2020 Nov 11. pii: 5973946. doi: 10.1093.
    PubMed     Abstract available


  219. BERZERO G, Di Stefano AL, Ronchi S, Bielle F, et al
    IDH-wildtype lower grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.
    Neuro Oncol. 2020 Nov 11. pii: 5973947. doi: 10.1093.
    PubMed     Abstract available


  220. GRAMATZKI D, Felsberg J, Roth P, Kaulich K, et al
    The molecular evolution of glioblastoma treated by gross total resection alone.
    Neuro Oncol. 2020 Nov 11. pii: 5973944. doi: 10.1093.
    PubMed    


  221. SAHEBJAM S, Forsyth PA, Tran ND, Arrington JA, et al
    Hypofractionated Stereotactic Re-Irradiation with Pembrolizumab and Bevacizumab in Patients with Recurrent High Grade Gliomas: Results from a Phase 1 Study.
    Neuro Oncol. 2020 Nov 11. pii: 5973945. doi: 10.1093.
    PubMed     Abstract available


  222. YI K, Zhan Q, Wang Q, Tan Y, et al
    PTRF/Cavin1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2.
    Neuro Oncol. 2020 Nov 3. pii: 5952479. doi: 10.1093.
    PubMed     Abstract available


  223. VITANZA NA, Biery MC, Myers C, Ferguson E, et al
    Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naive diffuse midline glioma models.
    Neuro Oncol. 2020 Nov 1. pii: 5948533. doi: 10.1093.
    PubMed     Abstract available


  224. MANJUNATH M, Yan J, Youn Y, Drucker KL, et al
    Functional analysis of low-grade glioma genetic variants predicts key target genes and transcription factors.
    Neuro Oncol. 2020 Nov 1. pii: 5948532. doi: 10.1093.
    PubMed     Abstract available


  225. DEJAEGHER J, Solie L, Hunin Z, Sciot R, et al
    DNA Methylation based glioblastoma subclassification is related to tumoral T cell infiltration and patient survival.
    Neuro Oncol. 2020 Nov 1. pii: 5948531. doi: 10.1093.
    PubMed     Abstract available


  226. KLEIN M, Drijver AJ, van den Bent MJ, Bromberg JC, et al
    Memory in low-grade glioma patients treated with radiotherapy or Temozolomide. A correlative analysis of EORTC study 22033-26033.
    Neuro Oncol. 2020 Nov 1. pii: 5948535. doi: 10.1093.
    PubMed     Abstract available


  227. SIEVERS P, Sill M, Schrimpf D, Stichel D, et al
    A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR.
    Neuro Oncol. 2020 Nov 1. pii: 5948536. doi: 10.1093.
    PubMed     Abstract available


  228. JI SY, Lee J, Lee JH, Lee ST, et al
    Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling.
    Neuro Oncol. 2020 Nov 1. pii: 5948534. doi: 10.1093.
    PubMed     Abstract available


    October 2020
  229. OSTROM QT, Patil N, Cioffi G, Waite K, et al
    CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.
    Neuro Oncol. 2020;22.
    PubMed     Abstract available


  230. TENG J, Hejazi S, Hiddingh L, Carvalho L, et al
    Corrigendum to: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Neuro Oncol. 2020 Oct 28. pii: 5942594. doi: 10.1093.
    PubMed    


  231. CICONE F, Carideo L, Scaringi C, Romano A, et al
    Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET.
    Neuro Oncol. 2020 Oct 23. pii: 5936979. doi: 10.1093.
    PubMed     Abstract available


  232. MYNAREK M, Rutkowski S
    Young children with medulloblastoma: Important open questions and the high-risk dilemma.
    Neuro Oncol. 2020 Oct 23. pii: 5936023. doi: 10.1093.
    PubMed    


  233. GONDI V, Mehta MP
    Radiotherapy Innovations to Optimize Brain Metastases Control.
    Neuro Oncol. 2020 Oct 22. pii: 5934824. doi: 10.1093.
    PubMed    


  234. BROSSIER NM, Thondapu S, Cobb OM, Dahiya S, et al
    Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine Neurofibromatosis-1 optic glioma.
    Neuro Oncol. 2020 Oct 20. pii: 5932401. doi: 10.1093.
    PubMed     Abstract available


  235. CHO SJ, Sunwoo L, Baik SH, Bae YJ, et al
    Brain Metastasis Detection using Machine Learning: A Systematic Review and Meta-analysis.
    Neuro Oncol. 2020 Oct 19. pii: 5930826. doi: 10.1093.
    PubMed     Abstract available


  236. GROSSMAN SA
    The Duration of Adjuvant Temozolomide in Patients with Glioblastoma and the Law of Diminishing Returns.
    Neuro Oncol. 2020 Oct 19. pii: 5930402. doi: 10.1093.
    PubMed    


  237. SKINNER KR, Nabors LB, Miller CR
    Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics.
    Neuro Oncol. 2020 Oct 19. pii: 5930390. doi: 10.1093.
    PubMed    


  238. ZHUANG H, Wang Y, Cheng C, Shi S, et al
    The efficacy of anlotinib instead of glucocorticoids for edema induced by brain metastases in NSCLC patients with anti-PD1/PDL-1 immunotherapy.
    Neuro Oncol. 2020 Oct 19. pii: 5930379. doi: 10.1093.
    PubMed    


  239. YOUNGBLOOD MW, Miyagishima DF, Jin L, Gupte T, et al
    Associations of Meningioma Molecular Subgroup and Tumor Recurrence.
    Neuro Oncol. 2020 Oct 17. pii: 5928913. doi: 10.1093.
    PubMed     Abstract available


  240. LAMBA N, Kearney RB, Catalano PJ, Hassett MJ, et al
    Population-based estimates of survival among elderly patients with brain metastases.
    Neuro Oncol. 2020 Oct 17. pii: 5929216. doi: 10.1093.
    PubMed     Abstract available


  241. BEIG N, Singh S, Bera K, Prasanna P, et al
    Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in Glioblastoma.
    Neuro Oncol. 2020 Oct 17. pii: 5929182. doi: 10.1093.
    PubMed     Abstract available


  242. BINDRA RS
    Penetrating the Brain Tumor Space with DNA Damage Response Inhibitors.
    Neuro Oncol. 2020 Oct 16. pii: 5924496. doi: 10.1093.
    PubMed    


  243. OPITZ CA, Turcan S
    From anti-aging drugs to cancer therapy: Is there a potential for sirtuin activators in gliomas?
    Neuro Oncol. 2020 Oct 16. pii: 5924499. doi: 10.1093.
    PubMed    


  244. ALNAHHAS I, Rayi A, Ong S, Giglio P, et al
    Management of gliomas in patients with Lynch Syndrome.
    Neuro Oncol. 2020 Oct 16. pii: 5924485. doi: 10.1093.
    PubMed    


  245. CHAMBERLAIN MC
    Leptomeningeal metastases: how best to assess response.
    Neuro Oncol. 2020;22:1417-1418.
    PubMed    


  246. ROSSI M, Gay L, Ambrogi F, Nibali MC, et al
    Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas.
    Neuro Oncol. 2020 Oct 13. pii: 5922564. doi: 10.1093.
    PubMed     Abstract available


    September 2020
  247. DAS S
    The ethics of neuro-oncology in the era of COVID-19: lessons to be learned.
    Neuro Oncol. 2020;22:1399.
    PubMed    


  248. XU W, Hu X, Zhang J
    Letter regarding article "Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion".
    Neuro Oncol. 2020;22:1400-1401.
    PubMed    


  249. KOTECHA R, Yomo S, Suh JH
    Response to letter regarding "Stereotactic radiosurgery for nonfunctioning pituitary adenomas: meta-analysis and International Society of Stereotactic Radiosurgery (ISRS) practice opinion".
    Neuro Oncol. 2020;22:1402-1403.
    PubMed    


  250. SHIREMAN JM, Ahmed AU
    Separate and not Equal: Sex Differences in JAM-A Tumor Suppression in Glioblastoma.
    Neuro Oncol. 2020 Sep 22. pii: 5909858. doi: 10.1093.
    PubMed    


  251. TSANG DS, Kim L, Liu ZA, Janzen L, et al
    Intellectual changes after radiation for children with brain tumors: which brain structures are most important?
    Neuro Oncol. 2020 Sep 16. pii: 5906521. doi: 10.1093.
    PubMed     Abstract available


  252. MILLER JJ, Cahill DP
    MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma.
    Neuro Oncol. 2020 Sep 14. pii: 5905585. doi: 10.1093.
    PubMed    


  253. WEI Y, Lu C, Zhou P, Zhao L, et al
    EIF4A3-induced circular RNA ASAP1(circASAP1) promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1/2 signaling.
    Neuro Oncol. 2020 Sep 14. pii: 5905565. doi: 10.1093.
    PubMed     Abstract available


  254. KHUONG-QUANG DA, Hansford JR
    Preoperative chemotherapy in medulloblastoma: A change in treatment paradigm?
    Neuro Oncol. 2020 Sep 12. pii: 5904992. doi: 10.1093.
    PubMed    


  255. JOHNSON RM, Phillips HS, Bais C, Brennan CW, et al
    Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma.
    Neuro Oncol. 2020 Sep 8. pii: 5902781. doi: 10.1093.
    PubMed     Abstract available


  256. BALANA C, Carrato C, Vaz MA
    Reply to: 'Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?'
    Neuro Oncol. 2020 Sep 4. pii: 5901531. doi: 10.1093.
    PubMed    


  257. PARK JW, Sahm F, Steffl B, Arrillaga-Romany I, et al
    TERT and DNMT1 expression predict sensitivity to decitabine in gliomas.
    Neuro Oncol. 2020 Sep 3. pii: 5901083. doi: 10.1093.
    PubMed     Abstract available


  258. KOTECHA R, Hall MD
    Impact of Radiotherapy Dosimetric Parameters on Neurocognitive Function in Brain Tumor Patients.
    Neuro Oncol. 2020 Sep 2. pii: 5900405. doi: 10.1093.
    PubMed    


    August 2020
  259. GUERREIRO STUCKLIN AS, Mueller S
    Opportunities for the treatment of NF1-associated low-grade gliomas: how to decide on the best treatment options for patients?
    Neuro Oncol. 2020 Aug 25. pii: 5896906. doi: 10.1093.
    PubMed    


  260. HE Y, Li J, Koga T, Ma J, et al
    Epidermal Growth Factor Receptor (EGFR) as a molecular determinant of glioblastoma response to dopamine receptor 2 (DRD2) inhibitors.
    Neuro Oncol. 2020 Aug 24. pii: 5896390. doi: 10.1093.
    PubMed     Abstract available


  261. ECKER J, Thatikonda V, Sigismondo G, Selt F, et al
    Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.
    Neuro Oncol. 2020 Aug 21. pii: 5895493. doi: 10.1093.
    PubMed     Abstract available


  262. NIE E, Jin X, Miao F, Yu T, et al
    TGF-beta1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT.
    Neuro Oncol. 2020 Aug 19. pii: 5894410. doi: 10.1093.
    PubMed     Abstract available


  263. ROSSMEISL JH, Herpai D, Quigley M, Cecere TE, et al
    Phase I trial of convection-enhanced delivery of IL13RA2 and EPHA2 receptor targeted cytotoxins in dogs with spontaneous intracranial gliomas.
    Neuro Oncol. 2020 Aug 19. pii: 5894210. doi: 10.1093.
    PubMed     Abstract available


  264. BOHM AK, DePetro J, Binding CE, Gerber A, et al
    In vitro modeling of glioblastoma initiation using PDGF-AA and p53-null neural progenitors.
    Neuro Oncol. 2020;22:1150-1161.
    PubMed     Abstract available


  265. SHI C, Ye Z, Han J, Ye X, et al
    BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.
    Neuro Oncol. 2020;22:1114-1125.
    PubMed     Abstract available


  266. WICK A, Kessler T, Platten M, Meisner C, et al
    Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
    Neuro Oncol. 2020;22:1162-1172.
    PubMed     Abstract available


  267. YANG WC, Chen YF, Yang CC, Wu PF, et al
    Hippocampal Avoidance Whole-brain Radiotherapy without Memantine in Preserving Neurocognitive Function for Brain Metastases: A Phase II Blinded Randomized Trial.
    Neuro Oncol. 2020 Aug 13. pii: 5892223. doi: 10.1093.
    PubMed     Abstract available


  268. JOO L, Park JE, Park SY, Nam SJ, et al
    Extensive Peritumoral Edema and Brain-to-Tumor Interface MR Imaging Features Enable Prediction of Brain Invasion in Meningioma: Development and Validation.
    Neuro Oncol. 2020 Aug 13. pii: 5892102. doi: 10.1093.
    PubMed     Abstract available


  269. DANIEL AGS, Park KY, Roland JL, Dierker D, et al
    Functional connectivity within glioblastoma impacts overall survival.
    Neuro Oncol. 2020 Aug 13. pii: 5892093. doi: 10.1093.
    PubMed     Abstract available


  270. TRAN AN, Horbinski C
    Mesenchymal stem-like cells in glioblastoma.
    Neuro Oncol. 2020 Aug 12. pii: 5891766. doi: 10.1093.
    PubMed    


  271. MILANO MT, Chiang VLS, Soltys SG, Wang TJC, et al
    Executive Summary from American Radium Society's Appropriate Use Criteria on Neurocognition after stereotactic radiosurgery for multiple brain metastases.
    Neuro Oncol. 2020 Aug 11. pii: 5891284. doi: 10.1093.
    PubMed     Abstract available


  272. GUPTA T, Chatterjee A, Patil V
    Extended adjuvant temozolomide in newly-diagnosed glioblastoma: is more less?
    Neuro Oncol. 2020 Aug 10. pii: 5890517. doi: 10.1093.
    PubMed    


  273. PACKER RJ, MacDonald TJ
    Integrated Analysis of Pediatric Low-Grade Glioma (PLGGs): Clinical Implications and the Path Forward.
    Neuro Oncol. 2020 Aug 8. pii: 5885400. doi: 10.1093.
    PubMed    


  274. FULTS DW
    Marauding Monocytes, Macrophages, and Microglia in Gliomas.
    Neuro Oncol. 2020 Aug 8. pii: 5885299. doi: 10.1093.
    PubMed    


  275. HOSSAIN JA, Miletic H
    Letter regarding "Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas".
    Neuro Oncol. 2020 Aug 8. pii: 5885399. doi: 10.1093.
    PubMed    


  276. MOHAN R, Liu AY, Brown PD, Mahajan A, et al
    Proton Therapy Reduces the Likelihood of High-Grade Radiation-Induced Lymphopenia in Glioblastoma Patients: Phase II Randomized Study of Protons vs. Photons.
    Neuro Oncol. 2020 Aug 5. pii: 5880625. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  277. ARANA E, Arribas LA
    Letter regarding "Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases".
    Neuro Oncol. 2020 Jul 31. pii: 5879447. doi: 10.1093.
    PubMed    


  278. CHOI YS, Bae S, Chang JH, Kang SG, et al
    Fully Automated Hybrid Approach to Predict the IDH Mutation Status of Gliomas via Deep Learning and Radiomics.
    Neuro Oncol. 2020 Jul 24. pii: 5876011. doi: 10.1093.
    PubMed     Abstract available


  279. WILCOX JA, Boire AA
    Palliation for all people: alleviating racial disparities in supportive care for brain metastases.
    Neuro Oncol. 2020 Jul 21. pii: 5874496. doi: 10.1093.
    PubMed    


  280. LAMBA N, Catalano PJ, Haas-Kogan DA, Wen PY, et al
    Utility of claims data for delineation of intracranial treatment among patients with brain metastases.
    Neuro Oncol. 2020 Jul 21. pii: 5874115. doi: 10.1093.
    PubMed    


  281. WORONIECKA K, Fecci PE
    Immuno-Synergy? Neoantigen Vaccines and Checkpoint Blockade in Glioblastoma.
    Neuro Oncol. 2020 Jul 21. pii: 5874112. doi: 10.1093.
    PubMed    


  282. CHILUKURI S, Jalali R
    Reassuring quality of life in younger childhood (<4 years) brain tumor survivors treated with proton beam therapy.
    Neuro Oncol. 2020 Jul 17. pii: 5873257. doi: 10.1093.
    PubMed    


  283. SCHMAINDA KM, Prah MA, Marques H, Kim E, et al
    Value of Dynamic Contrast Perfusion MRI to Predict Early Response to Bevacizumab in Newly Diagnosed Glioblastoma: Results from ACRIN 6686 Multi-Center Trial.
    Neuro Oncol. 2020 Jul 17. pii: 5873138. doi: 10.1093.
    PubMed     Abstract available


  284. HOLLON TC, Pandian B, Urias E, Save AV, et al
    Rapid, label-free detection of diffuse glioma recurrence using intraoperative stimulated Raman histology and deep neural networks.
    Neuro Oncol. 2020 Jul 16. pii: 5872473. doi: 10.1093.
    PubMed     Abstract available


  285. JIN L, Shi F, Chun Q, Chen H, et al
    Artificial Intelligence Neuropathologist for Glioma Classification using Deep Learning on Hematoxylin and Eosin Stained Slide images and Molecular Markers.
    Neuro Oncol. 2020 Jul 14. pii: 5871429. doi: 10.1093.
    PubMed     Abstract available


  286. SANTANGELO A, Rossato M, Lombardi G, Benfatto S, et al
    A Molecular Signature associated with prolonged survival in Glioblastoma patients treated with Regorafenib.
    Neuro Oncol. 2020 Jul 14. pii: 5871069. doi: 10.1093.
    PubMed     Abstract available


  287. ALMAHARIQ MF, Quinn TJ, Arden JD, Roskos PT, et al
    Pulsed Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma.
    Neuro Oncol. 2020 Jul 13. pii: 5870764. doi: 10.1093.
    PubMed     Abstract available


  288. BAKAS S, Ormond DR, Alfaro KD, Smits M, et al
    iGLASS: Imaging integration into the Glioma Longitudinal AnalySiS Consortium.
    Neuro Oncol. 2020 Jul 9. pii: 5869362. doi: 10.1093.
    PubMed    


  289. KARREMAN MA, Winkler F
    Targeting an adhesion molecule to prevent brain colonization of lung cancer.
    Neuro Oncol. 2020;22:899-900.
    PubMed    


  290. GEURTS M, van den Bent MJ
    Fast-growing oligodendrogliomas are aggressive tumors-the real life biomarker?
    Neuro Oncol. 2020;22:907-908.
    PubMed    


  291. COLO F, Larrouquere L, Rivoirard R, Loiseau H, et al
    Bevacizumab in progressive disseminated atypical choroid plexus papilloma in adults.
    Neuro Oncol. 2020;22:1046-1047.
    PubMed    


  292. JAIN R, Johnson DR, Patel SH, Castillo M, et al
    "Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas.
    Neuro Oncol. 2020;22:936-943.
    PubMed     Abstract available


  293. ROUX A, Tauziede-Espariat A, Zanello M, Peeters S, et al
    Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults.
    Neuro Oncol. 2020;22:993-1005.
    PubMed     Abstract available


  294. AZIZI AA, Walker DA, Liu JF, Sehested A, et al
    NF1 optic pathway glioma. Analysing risk factors for visual outcome and indications to treat.
    Neuro Oncol. 2020 Jul 6. pii: 5867970. doi: 10.1093.
    PubMed     Abstract available


  295. VENKATARAMANI V, Tanev DI, Kuner T, Wick W, et al
    Synaptic Input to Brain Tumors: Clinical Implications.
    Neuro Oncol. 2020 Jul 5. pii: 5867510. doi: 10.1093.
    PubMed     Abstract available


  296. CARAI A, Locatelli F, Mastronuzzi A
    Delayed referral of pediatric brain tumors during COVID-19 pandemic.
    Neuro Oncol. 2020 Jul 5. pii: 5867513. doi: 10.1093.
    PubMed    


  297. DUNN GP, Cloughesy TF, Maus MV, Prins RM, et al
    Emerging Immunotherapies for Malignant Glioma: From Immunogenomics to Cell Therapy.
    Neuro Oncol. 2020 Jul 2. pii: 5866670. doi: 10.1093.
    PubMed     Abstract available


  298. VAN DEN BENT M, Eoli M, Sepulveda JM, Smits M, et al
    INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
    Neuro Oncol. 2020 Jul 1. pii: 5866079. doi: 10.1093.
    PubMed    


    June 2020
  299. ZHANG A, Tao W, Zhai K, Fang X, et al
    Protein Sumoylation with SUMO1 Promoted by Pin1 in Glioma Stem Cells Augments Glioblastoma Malignancy.
    Neuro Oncol. 2020 Jun 27. pii: 5864095. doi: 10.1093.
    PubMed     Abstract available


  300. TURAGA SM, Silver DJ, Bayik D, Paouri E, et al
    JAM-A functions as a female microglial tumor suppressor in glioblastoma.
    Neuro Oncol. 2020 Jun 27. pii: 5864028. doi: 10.1093.
    PubMed     Abstract available


  301. VAN TELLINGEN O, de Gooijer MC, Sarkaria JN, Elmquist WF, et al
    Comments on: "Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity".
    Neuro Oncol. 2020 Jun 18. pii: 5859434. doi: 10.1093.
    PubMed    


  302. BOXERMAN JL, Quarles CC, Hu LS, Erickson BJ, et al
    Consensus Recommendations for a Dynamic Susceptibility Contrast MRI Protocol for Use in High-Grade Gliomas.
    Neuro Oncol. 2020 Jun 9. pii: 5855183. doi: 10.1093.
    PubMed     Abstract available


  303. EATON BR, Yock TI
    Radiation for Pediatric Low Grade Gliomas: who will benefit and how late is soon enough?
    Neuro Oncol. 2020 Jun 9. pii: 5855151. doi: 10.1093.
    PubMed    


  304. JARAIZ-RODRIGUEZ M, Talaveron R, Garcia-Vicente L, Pelaz SG, et al
    Erratum to 'Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo'.
    Neuro Oncol. 2020 Jun 9. pii: 5854970. doi: 10.1093.
    PubMed    


  305. BENNETT J, Bouffet E
    Neuro-oncology in adolescents and young adults-an unmet need.
    Neuro Oncol. 2020;22:752-753.
    PubMed    


  306. HU LS, Swanson KR
    Roadmap for the clinical integration of radiomics in neuro-oncology.
    Neuro Oncol. 2020;22:743-745.
    PubMed    


  307. GROSSMAN SA, Romo CG, Rudek MA, Supko J, et al
    Baseline Requirements for Novel Agents Being Considered for Phase II/III Brain Cancer Efficacy Trials:Conclusions from the Adult Brain Tumor Consortium's First Workshop on CNS Drug Delivery.
    Neuro Oncol. 2020 Jun 7. pii: 5854364. doi: 10.1093.
    PubMed    


  308. LEACH JL, Roebker J, Schafer A, Baugh J, et al
    MR Imaging features of Diffuse Intrinsic Pontine Glioma (DIPG) and Relationship to Overall Survival: Report from the International DIPG Registry.
    Neuro Oncol. 2020 Jun 6. pii: 5854320. doi: 10.1093.
    PubMed     Abstract available


  309. ZHANG LH, Yin YH, Chen HZ, Feng SY, et al
    TRIM24 Promotes Stemness and Invasiveness of Glioblastoma Cells via Activating SOX2 Expression.
    Neuro Oncol. 2020 Jun 3. pii: 5850997. doi: 10.1093.
    PubMed     Abstract available


  310. KOTECHA R, Mehta MP
    Extreme Hypofractionation for Newly Diagnosed Glioblastoma: Rationale, Dose, Techniques, and Outcomes.
    Neuro Oncol. 2020 Jun 1. pii: 5849843. doi: 10.1093.
    PubMed    


  311. MASSIMINO M, Giangaspero F
    Editorial: High-grade gliomas in adolescents and young adults reveal histomolecular differences vis-a-vis their adult and pediatric counterparts.
    Neuro Oncol. 2020 Jun 1. pii: 5849851. doi: 10.1093.
    PubMed    


  312. HAGGIAGI A, Lassman AB
    Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?
    Neuro Oncol. 2020 Jun 1. pii: 5849858. doi: 10.1093.
    PubMed    


  313. SAMMONS S, Van Swearingen AED, Anders CK
    Receptor Discordance in Breast Cancer Brain Metastases: When Knowledge is Power.
    Neuro Oncol. 2020 Jun 1. pii: 5849911. doi: 10.1093.
    PubMed    


    May 2020
  314. BUCCARELLI M, Lulli V, Giuliani A, Signore M, et al
    Deregulated expression of the imprinted DLK1-DIO3 region in Glioblastoma Stem-like Cells: tumor suppressor role of lncRNA MEG3.
    Neuro Oncol. 2020 May 27. pii: 5847771. doi: 10.1093.
    PubMed     Abstract available


  315. KAUR E, Nair J, Ghorai A, Mishra SV, et al
    Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevent glioblastoma recurrence.
    Neuro Oncol. 2020 May 27. pii: 5847629. doi: 10.1093.
    PubMed     Abstract available


  316. BARONI LV, Sampor C, Gonzalez A, Lubieniecki F, et al
    Bridging the treatment gap in infant medulloblastoma: Molecularly informed outcomes of a globally feasible regimen.
    Neuro Oncol. 2020 May 15. pii: 5837622. doi: 10.1093.
    PubMed     Abstract available


  317. DI STEFANO AL, Picca A, Saragoussi E, Bielle F, et al
    Clinical, molecular and radiomic profile of gliomas with FGFR3-TACC3 fusions.
    Neuro Oncol. 2020 May 15. pii: 5837595. doi: 10.1093.
    PubMed     Abstract available


  318. SANTANA-CODINA N, Gonzalez J, Sierra A
    Reply to Letter to the Editor.
    Neuro Oncol. 2020;22:734-735.
    PubMed    


  319. BRANDSMA D, van den Bent MJB
    Quantification of leptomeningeal metastases from solid tumors remains a challenging issue.
    Neuro Oncol. 2020;22:592-593.
    PubMed    


  320. LOBBOUS M, Nabors LB
    A troublesome burden, the amplification of EGFR in glioblastoma!
    Neuro Oncol. 2020;22:594-595.
    PubMed    


  321. SCHELL M, Pfluger I, Brugnara G, Isensee F, et al
    Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.
    Neuro Oncol. 2020 May 11. pii: 5836012. doi: 10.1093.
    PubMed     Abstract available


  322. GOLDMAN S, Pollack IF, Jakacki RI, Billups CA, et al
    Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report.
    Neuro Oncol. 2020 May 11. pii: 5836011. doi: 10.1093.
    PubMed     Abstract available


  323. GRIL B, Wei D, Zimmer AS, Robinson C, et al
    A HER2 Antibody Drug Conjugate Controls Growth of Breast Cancer Brain Metastases in Hematogenous Xenograft Models, with Heterogeneous Blood-Tumor Barrier Penetration Unlinked to a Passive Marker.
    Neuro Oncol. 2020 May 9. pii: 5835334. doi: 10.1093.
    PubMed     Abstract available


  324. ECKEL-PASSOW JE, Drucker KL, Kollmeyer TM, Kosel ML, et al
    Adult Diffuse Glioma GWAS by Molecular Subtype Identifies Variants in D2HGDH and FAM20C.
    Neuro Oncol. 2020 May 9. pii: 5835318. doi: 10.1093.
    PubMed     Abstract available


  325. BERNHARDT D, Wick W, Weiss SE, Sahgal A, et al
    Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas.
    Neuro Oncol. 2020 May 5. pii: 5829911. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  326. HANNA C, Kurian KM, Williams K, Watts C, et al
    Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
    Neuro Oncol. 2020 Apr 29. pii: 5826799. doi: 10.1093.
    PubMed     Abstract available


  327. TABRIZI S, Trippa L, Cagney D, Tanguturi S, et al
    A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the Elderly.
    Neuro Oncol. 2020 Apr 27. pii: 5825707. doi: 10.1093.
    PubMed     Abstract available


  328. BALANA C, Vaz MA, Sepulveda JM, Mesia C, et al
    A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01).
    Neuro Oncol. 2020 Apr 24. pii: 5824410. doi: 10.1093.
    PubMed     Abstract available


  329. WEN PY, Weller M, Lee EQ, Alexander BA, et al
    Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.
    Neuro Oncol. 2020 Apr 24. pii: 5824407. doi: 10.1093.
    PubMed     Abstract available


  330. HUANG RY, Young RJ, Ellingson BM, Veeraraghavan H, et al
    Volumetric Analysis of IDH-Mutant Lower-Grade Glioma: A Natural History Study of Tumor Growth Rates Before and After Treatment.
    Neuro Oncol. 2020 Apr 24. pii: 5824395. doi: 10.1093.
    PubMed     Abstract available


  331. YANG WB, Hsu CC, Hsu TI, Liou JP, et al
    Increased activation of HDAC1/2/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma.
    Neuro Oncol. 2020 Apr 24. pii: 5824394. doi: 10.1093.
    PubMed     Abstract available


  332. CLUCERU J, Nelson SJ, Wen Q, Phillips JJ, et al
    Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas.
    Neuro Oncol. 2020 Apr 22. pii: 5823723. doi: 10.1093.
    PubMed     Abstract available


  333. DHALL G, O'Neil SH, Ji L, Haley K, et al
    Excellent Outcome of Young Children with Nodular Desmoplastic Medulloblastoma Treated on "Head Start" III: A Multi-Institutional, Prospective Clinical Trial.
    Neuro Oncol. 2020 Apr 18. pii: 5821791. doi: 10.1093.
    PubMed     Abstract available


  334. BELLAT V, Alcaina Y, Tung CH, Ting R, et al
    A Combined Approach of Convection-Enhanced Delivery of Peptide Nanofiber Reservoir to Prolong Delivery of DM1 for Diffuse Intrinsic Pontine Glioma Treatment.
    Neuro Oncol. 2020 Apr 17. pii: 5821265. doi: 10.1093.
    PubMed     Abstract available


  335. KRIEGER TG, Tirier SM, Park J, Jechow K, et al
    Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics.
    Neuro Oncol. 2020 Apr 16. pii: 5820825. doi: 10.1093.
    PubMed     Abstract available


  336. KEUNEN O, Niclou SP
    A prominent role for MR spectroscopy in the clinical management of brain tumors?
    Neuro Oncol. 2020 Apr 15. pii: 5820221. doi: 10.1093.
    PubMed    


  337. MOHILE NA, Blakeley JO, Gatson NTN, Hottinger AF, et al
    Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic.
    Neuro Oncol. 2020 Apr 11. pii: 5818980. doi: 10.1093.
    PubMed     Abstract available


  338. GUERRINI-ROUSSEAU L, Abbas R, Huybrechts S, Kieffer-Renaux V, et al
    Role of neoadjuvant chemotherapy in metastatic medulloblastoma: a comparative study in 92 children.
    Neuro Oncol. 2020 Apr 8. pii: 5817932. doi: 10.1093.
    PubMed     Abstract available


  339. FUKUOKA K, Mamatjan Y, Tatevossian R, Zapotocky M, et al
    Clinical impact of combined epigenetic and molecular analysis of pediatric low grade gliomas.
    Neuro Oncol. 2020 Apr 3. pii: 5815300. doi: 10.1093.
    PubMed     Abstract available


  340. TABRIZI S, Shih HA
    The Path Forward for Radiation Therapy in the Management of Low-Grade Gliomas.
    Neuro Oncol. 2020 Apr 2. pii: 5815323. doi: 10.1093.
    PubMed    


  341. ULLRICH NJ, Prabhu SP, Reddy AT, Fisher MJ, et al
    A Phase II Study of Continuous Oral mTOR Inhibitor Everolimus for Recurrent, Radiographic-Progressive Neurofibromatosis Type 1-Associated Pediatric Low-Grade Glioma: A Neurofibromatosis Clinical Trials Consortium Study.
    Neuro Oncol. 2020 Apr 1. pii: 5814308. doi: 10.1093.
    PubMed     Abstract available


  342. LEE S, Latha K, Manyam G, Yang Y, et al
    Role of CX3CR1 Signaling in Malignant Transformation of Gliomas.
    Neuro Oncol. 2020 Apr 1. pii: 5814292. doi: 10.1093.
    PubMed     Abstract available


    March 2020
  343. GODA JS, Dutta D, Krishna U, Goswami S, et al
    Hippocampal radiotherapy dose-constraints for predicting long-term neurocognitive outcomes: Mature data from a prospective trial in young patients with brain tumors.
    Neuro Oncol. 2020 Mar 30. pii: 5813654. doi: 10.1093.
    PubMed     Abstract available


  344. TAYLOR JT, Ellison S, Pandele A, Wood S, et al
    Actinomycin D Downregulates Sox2 and Improves Survival in Preclinical Models of Recurrent Glioblastoma.
    Neuro Oncol. 2020 Mar 30. pii: 5813520. doi: 10.1093.
    PubMed     Abstract available


  345. YOSHIDA GJ
    Comment on "GRP94 promotes brain metastasis by engaging pro-survival autophagy".
    Neuro Oncol. 2020 Mar 27. pii: 5812835. doi: 10.1093.
    PubMed    


  346. FEDERICI L, Capelle L, Annereau M, Bielle F, et al
    5-Azacitidine in Patients with IDH1/2-mutant Recurrent Glioma.
    Neuro Oncol. 2020 Mar 26. pii: 5812065. doi: 10.1093.
    PubMed    


  347. PENG J, Zhou H, Tang O, Chang K, et al
    Evaluation of RAPNO criteria in medulloblastoma and other leptomeningeal seeding tumors using MRI and clinical data.
    Neuro Oncol. 2020 Mar 26. pii: 5811685. doi: 10.1093.
    PubMed     Abstract available


  348. SONG J, Kadaba P, Kravitz A, Hormigo A, et al
    Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.
    Neuro Oncol. 2020 Mar 20. pii: 5810282. doi: 10.1093.
    PubMed     Abstract available


  349. GILL CM, Loewenstern J, Rutland JW, Arib H, et al
    Recurrent IDH Mutations in High-Grade Meningioma.
    Neuro Oncol. 2020 Mar 17. pii: 5808805. doi: 10.1093.
    PubMed    


  350. BAILEY CP, Figueroa M, Gangadharan A, Yang Y, et al
    Pharmacologic inhibition of lysine specific demethylase-1 (LSD1) as a therapeutic and immune-sensitization strategy in pediatric high grade glioma (pHGG).
    Neuro Oncol. 2020 Mar 13. pii: 5804621. doi: 10.1093.
    PubMed     Abstract available


  351. MATHUR R, Zhang Y, Grimmer MR, Hong C, et al
    MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
    Neuro Oncol. 2020 Mar 13. pii: 5804625. doi: 10.1093.
    PubMed     Abstract available


  352. PUDUVALLI VK, Wu J, Yuan Y, Armstrong TS, et al
    A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma.
    Neuro Oncol. 2020 Mar 13. pii: 5804658. doi: 10.1093.
    PubMed     Abstract available


  353. GORELYSHEV A, Mazerkina N, Medvedeva O, Vasilyev E, et al
    Second-hit APC mutation in a familial adamantinomatous craniopharyngioma.
    Neuro Oncol. 2020 Mar 12. pii: 5805241. doi: 10.1093.
    PubMed    


  354. EBERHART C
    Astrocytes - New Stars In The Medulloblastoma Firmament.
    Neuro Oncol. 2020 Mar 11. pii: 5802783. doi: 10.1093.
    PubMed    


  355. KHATUA S, Cooper LJN, Sandberg DI, Ketonen L, et al
    Phase I study of intraventricular infusions of autologous ex-vivo-expanded NK cells in children with recurrent medulloblastoma and ependymoma.
    Neuro Oncol. 2020 Mar 10. pii: 5802287. doi: 10.1093.
    PubMed     Abstract available


  356. LAMBA N, Mehanna E, Kearney RB, Catalano PJ, et al
    Racial disparities in supportive medication use among older patients with brain metastases: A population-based analysis.
    Neuro Oncol. 2020 Mar 9. pii: 5800995. doi: 10.1093.
    PubMed     Abstract available


  357. LIU CJ, Schaettler M, Blaha DT, Bowman-Kirigin JA, et al
    Treatment of an Aggressive Orthotopic Murine Glioblastoma Model with Combination Checkpoint Blockade and a Multivalent Neoantigen Vaccine.
    Neuro Oncol. 2020 Mar 5. pii: 5781186. doi: 10.1093.
    PubMed     Abstract available


  358. SIDDAWAY R, Hawkins C
    Modeling DIPG in the mouse brainstem.
    Neuro Oncol. 2020;22:307-308.
    PubMed    


  359. KOTECHA R, Sahgal A, Rubens M, De Salles A, et al
    Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion.
    Neuro Oncol. 2020;22:318-332.
    PubMed     Abstract available


  360. LASOCKI A, Khoo C, Lau PKH, Kok DL, et al
    High-resolution MRI demonstrates that more than 90% of small intracranial melanoma metastases develop in close relationship to the leptomeninges.
    Neuro Oncol. 2020;22:423-432.
    PubMed     Abstract available


    February 2020
  361. STOECKLEIN VM, Stoecklein S, Galie F, Ren J, et al
    Resting-state fMRI Detects Alterations in Whole Brain Connectivity Related to Tumor Biology in Glioma Patients.
    Neuro Oncol. 2020 Feb 28. pii: 5764143. doi: 10.1093.
    PubMed     Abstract available


  362. JIANG H, Yang K, Ren X, Cui Y, et al
    Retraction notice: Diffuse midline glioma with H3 K27M mutation: a comparison integrating the clinical, radiological, and molecular features between adult and pediatric patients.
    Neuro Oncol. 2020 Feb 25. pii: 5756150. doi: 10.1093.
    PubMed    


  363. LIM M, Pant A
    Understanding innate immune response in Glioblastoma in search for a way forward.
    Neuro Oncol. 2020 Feb 22. pii: 5751793. doi: 10.1093.
    PubMed    


  364. HIMES BT, Peterson TE, de Mooij T, Garcia MLMC, et al
    The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction.
    Neuro Oncol. 2020 Feb 21. pii: 5742588. doi: 10.1093.
    PubMed     Abstract available


  365. MENDEZ FM, Nunez FJ, Garcia-Fabiani MB, Haase S, et al
    Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease.
    Neuro Oncol. 2020;22:195-206.
    PubMed     Abstract available


  366. BALASUBRAMANIYAN V, Bhat K
    Targeting pyrimidine metabolism for glioblastoma therapy.
    Neuro Oncol. 2020;22:169-170.
    PubMed    


  367. OSTROM QT, Kruchko C, Barnholtz-Sloan JS
    Pilocytic astrocytomas: where do they belong in cancer reporting?
    Neuro Oncol. 2020;22:298-300.
    PubMed    



  368. Corrigendum to Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.
    Neuro Oncol. 2020 Feb 18. pii: 5740122. doi: 10.1093.
    PubMed    


  369. EATON BR, Goldberg S, Tarbell NJ, Lawell MP, et al
    Long-term Health Related Quality of Life in Pediatric Brain Tumor Survivors Treated with Proton Radiotherapy at <4 Years of Age.
    Neuro Oncol. 2020 Feb 17. pii: 5737810. doi: 10.1093.
    PubMed     Abstract available


  370. MUNSTERBERG J, Loreth D, Brylka L, Werner S, et al
    ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium.
    Neuro Oncol. 2020 Feb 17. pii: 5737760. doi: 10.1093.
    PubMed     Abstract available


  371. PACKER RJ, Iavarone A, Jones DTW, Blakeley JO, et al
    Implications of New Understandings of Gliomas in Children and Adults with NF1: Report of a Consensus Conference.
    Neuro Oncol. 2020 Feb 14. pii: 5736008. doi: 10.1093.
    PubMed     Abstract available


  372. FRITAH S, Niclou SP
    Dual blockade of STAT3 and EGFR, a key to unlock drug resistance in Glioblastoma?
    Neuro Oncol. 2020 Feb 14. pii: 5736011. doi: 10.1093.
    PubMed    


  373. TIWARI V, Daoud EV, Hatanpaa KJ, Gao A, et al
    Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness.
    Neuro Oncol. 2020 Feb 14. pii: 5735772. doi: 10.1093.
    PubMed     Abstract available


  374. SASTRY NG, Wan X, Huang T, Alvarez AA, et al
    LY6K Promotes Glioblastoma Tumorigenicity via CAV-1-Mediated ERK1/2 Signaling Enhancement.
    Neuro Oncol. 2020 Feb 14. pii: 5735689. doi: 10.1093.
    PubMed     Abstract available


  375. ACHARYA S, Liu JF, Tatevossian RG, Chiang J, et al
    Risk stratification in pediatric low-grade glioma and glioneuronal tumor treated with radiation therapy: An integrated clinicopathologic and molecular analysis.
    Neuro Oncol. 2020 Feb 13. pii: 5734990. doi: 10.1093.
    PubMed     Abstract available


  376. KAUFMANN TJ, Smits M, Boxerman J, Huang R, et al
    Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases (BTIP-BM).
    Neuro Oncol. 2020 Feb 12. pii: 5734626. doi: 10.1093.
    PubMed     Abstract available


  377. ZINNHARDT B, Muther M, Roll W, Backhaus P, et al
    TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma.
    Neuro Oncol. 2020 Feb 12. pii: 5734268. doi: 10.1093.
    PubMed     Abstract available


  378. SPERDUTO PW, Mesko S, Li J, Cagney D, et al
    Estrogen, Progesterone and HER2 Receptor Discordance Between Primary Tumor and Brain Metastases in Breast Cancer and Its Effect on Treatment and Survival.
    Neuro Oncol. 2020 Feb 8. pii: 5731396. doi: 10.1093.
    PubMed     Abstract available


  379. DE VRIES F
    Letter regarding "Cognitive outcomes in meningioma patients undergoing surgery: individual changes over time and predictors of late cognitive functioning".
    Neuro Oncol. 2020 Feb 6. pii: 5728672. doi: 10.1093.
    PubMed    


  380. ROUX A, Pallud J, Saffroy R, Edjlali-Goujon M, et al
    High-grade gliomas in adolescents and young adults highlight histomolecular differences with their adult and paediatric counterparts.
    Neuro Oncol. 2020 Feb 6. pii: 5728472. doi: 10.1093.
    PubMed     Abstract available


  381. HAN MZ, Huang B, Ni SL, Wang J, et al
    A validated prognostic nomogram for patients with newly diagnosed lower-grade gliomas in a large-scale Asian cohort.
    Neuro Oncol. 2020 Feb 6. pii: 5728477. doi: 10.1093.
    PubMed    


  382. BAXTER PA, Su JM, Onar-Thomas A, Billups CA, et al
    A Phase I/II Study of Veliparib (ABT-888) with Radiation and Temozolomide in Newly Diagnosed Diffuse Pontine Glioma: A Pediatric Brain Tumor Consortium Study.
    Neuro Oncol. 2020 Feb 3. pii: 5721145. doi: 10.1093.
    PubMed     Abstract available


    January 2020
  383. AZOULAY M, Chang SD, Gibbs IC, Hancock SL, et al
    A Phase I/II Trial of 5-Fraction Stereotactic Radiosurgery with 5-mm Margins with Concurrent Temozolomide in Newly Diagnosed Glioblastoma: Primary Outcomes.
    Neuro Oncol. 2020 Jan 31. pii: 5718251. doi: 10.1093.
    PubMed     Abstract available


  384. RIJNEN SJM, De Baene W, Rutten GM, Gehring K, et al
    In reply to the letter to the editor regarding 'Cognitive outcomes in meningioma patients undergoing surgery: Individual changes over time and predictors of late cognitive functioning'.
    Neuro Oncol. 2020 Jan 30. pii: 5718243. doi: 10.1093.
    PubMed    


  385. BREEN WG, Anderson SK, Carrero XW, Brown PD, et al
    Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.
    Neuro Oncol. 2020 Jan 30. pii: 5718239. doi: 10.1093.
    PubMed     Abstract available


  386. LEE EQ, Weller M, Sul J, Bagley SJ, et al
    Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
    Neuro Oncol. 2020 Jan 24. pii: 5715205. doi: 10.1093.
    PubMed     Abstract available


  387. HULSBERGEN AFC, Claes A, Kavouridis VK, Ansaripour A, et al
    Subtype switching in breast cancer brain metastases: a multicenter analysis.
    Neuro Oncol. 2020 Jan 23. pii: 5714300. doi: 10.1093.
    PubMed     Abstract available


  388. MUSKENS IS, de Smith AJ, Zhang C, Hansen HM, et al
    Germline cancer predisposition variants and pediatric glioma: a population-based study in California.
    Neuro Oncol. 2020 Jan 23. pii: 5714303. doi: 10.1093.
    PubMed     Abstract available


  389. RAO G, Sonabend A, Heimberger AB
    Are radiation and response biomarkers the missing elements for efficacious immunotherapy for glioma patients?
    Neuro Oncol. 2020 Jan 22. pii: 5714174. doi: 10.1093.
    PubMed    


  390. MOURAVIEV A, Detsky J, Sahgal A, Ruschin M, et al
    Use of Radiomics for the Prediction of Local Control of Brain Metastases After Stereotactic Radiosurgery.
    Neuro Oncol. 2020 Jan 20. pii: 5709657. doi: 10.1093.
    PubMed     Abstract available


  391. COMBA A, Dunn PJ, Argento AE, Kadiyala P, et al
    FYN tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates anti-glioma immune responses.
    Neuro Oncol. 2020 Jan 17. pii: 5707582. doi: 10.1093.
    PubMed     Abstract available


  392. CIMINO PJ
    Analogous survival for patients with glioblastoma diagnosed by either histopathological or molecular features.
    Neuro Oncol. 2020 Jan 17. pii: 5707595. doi: 10.1093.
    PubMed    


  393. POPOVSKI D, Huang A
    Targeting MEK/MELK in atypical teratoid rhabdoid tumor: a treatment approach aimed at exploiting blood-brain barrier deficiencies.
    Neuro Oncol. 2020;22:3-4.
    PubMed    


  394. TRIFILETTI DM, Brown PD
    Leptomeningeal disease following local brain irradiation: a new frontier.
    Neuro Oncol. 2020;22:5-6.
    PubMed    


  395. TEW BY, Legendre C, Schroeder MA, Triche T, et al
    Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones.
    Neuro Oncol. 2020;22:70-83.
    PubMed     Abstract available


  396. TERABE M, Gilbert MR
    Another layer of immune complication in glioblastoma: ICOS-ICOSL.
    Neuro Oncol. 2020 Jan 7. pii: 5697440. doi: 10.1093.
    PubMed    


  397. LAMBA N, Kearney RB, Mehanna E, Catalano PJ, et al
    Utility of claims data for identification of date of diagnosis of brain metastases.
    Neuro Oncol. 2020 Jan 6. pii: 5697047. doi: 10.1093.
    PubMed    


  398. PATEL RR, Verma V, Miller AB, Lin TA, et al
    Exclusion of Patients with Brain Metastases from Cancer Clinical Trials.
    Neuro Oncol. 2020 Jan 4. pii: 5695909. doi: 10.1093.
    PubMed    


    December 2019
  399. JARAIZ-RODRIGUEZ M, Talaveron R, Garcia-Vicente L, Pelaz SG, et al
    Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth and enhances survival in mouse models in vivo.
    Neuro Oncol. 2019 Dec 28. pii: 5688710. doi: 10.1093.
    PubMed     Abstract available


  400. NASSIRI F, Zadeh G
    How should we manage incidental meningiomas?
    Neuro Oncol. 2019 Dec 25. pii: 5686813. doi: 10.1093.
    PubMed    


  401. XUE J, Wang B, Ming Y, Liu X, et al
    Deep-learning-based Detection and Segmentation-assisted Management on Brain Metastases.
    Neuro Oncol. 2019 Dec 23. pii: 5684915. doi: 10.1093.
    PubMed     Abstract available


  402. LANGEN KJ, Galldiks N, Lohmann P
    Combined FET PET/ADC mapping: improved imaging of glioma infiltration?
    Neuro Oncol. 2019 Dec 20. pii: 5681898. doi: 10.1093.
    PubMed    


  403. HUANG RY, Guenette JP
    Non-invasive Diagnosis of H3 K27M Mutant Midline Glioma.
    Neuro Oncol. 2019 Dec 20. pii: 5681667. doi: 10.1093.
    PubMed    


  404. RUDA R, Soffietti R
    Does an Optimal Management of Brain Metastases from Oncogenic-Driver Non-Small Cell Lung Cancer Exist?
    Neuro Oncol. 2019 Dec 20. pii: 5681666. doi: 10.1093.
    PubMed    


  405. HAIDER AS, van den Bent M, Wen PY, Vogelbaum MA, et al
    Towards a standard pathological and molecular characterization of recurrent glioma in adults: a RANO effort.
    Neuro Oncol. 2019 Dec 17. pii: 5679607. doi: 10.1093.
    PubMed     Abstract available


  406. CLOUGHESY TF, Brenner A, de Groot JF, Butowski NA, et al
    A randomized controlled phase III study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).
    Neuro Oncol. 2019 Dec 17. pii: 5679576. doi: 10.1093.
    PubMed     Abstract available


  407. BRENNER AJ, Peters KB, Vredenburgh J, Bokstein F, et al
    Safety and efficacy of VB-111, an anti-cancer gene-therapy, in patients with recurrent glioblastoma: results of a phase I/II study.
    Neuro Oncol. 2019 Dec 17. pii: 5679561. doi: 10.1093.
    PubMed     Abstract available


  408. ARNOLD A, Yuan M, Price A, Harris L, et al
    Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity.
    Neuro Oncol. 2019 Dec 16. pii: 5679447. doi: 10.1093.
    PubMed     Abstract available


  409. ENE CI, Kreuser SA, Jung M, Zhang H, et al
    Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma.
    Neuro Oncol. 2019 Dec 3. pii: 5650878. doi: 10.1093.
    PubMed     Abstract available


  410. RUSS JB, Weiss WA
    Conversations on mutism: risk-stratification for cerebellar mutism based on medulloblastoma subtype.
    Neuro Oncol. 2019 Dec 3. pii: 5650866. doi: 10.1093.
    PubMed    


    November 2019
  411. DAVIS FG, Smith TR, Gittleman HR, Ostrom QT, et al
    Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995-2015.
    Neuro Oncol. 2019 Nov 30. pii: 5648949. doi: 10.1093.
    PubMed    


  412. CARROLL SL, Longo JF
    Salinomycin targets the genome of radioresistant cells in glioblastomas.
    Neuro Oncol. 2019 Nov 30. pii: 5648122. doi: 10.1093.
    PubMed    


  413. ANEJA S, Omuro A
    Imaging biomarkers for brain metastases: more than meets the eye.
    Neuro Oncol. 2019 Nov 28. pii: 5645031. doi: 10.1093.
    PubMed    


  414. CAM M, Charan M, Welker AM, Dravid P, et al
    DeltaNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma.
    Neuro Oncol. 2019 Nov 25. pii: 5640296. doi: 10.1093.
    PubMed     Abstract available


  415. DE GROOT J, Penas-Prado M, Alfaro-Munoz KD, Hunter K, et al
    Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.
    Neuro Oncol. 2019 Nov 22. pii: 5637917. doi: 10.1093.
    PubMed     Abstract available


  416. GEHRING K, Stuiver MM, Visser E, Kloek C, et al
    A pilot randomized controlled trial of exercise to improve cognitive performance in patients with stable glioma: a proof of concept.
    Neuro Oncol. 2019 Nov 21. pii: 5637916. doi: 10.1093.
    PubMed     Abstract available


  417. VAN DEN BENT M, Eoli M, Sepulveda JM, Smits M, et al
    INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFRamplified glioblastoma.
    Neuro Oncol. 2019 Nov 20. pii: 5634209. doi: 10.1093.
    PubMed     Abstract available


  418. LIU H, Sun Y, O'Brien JA, Franco-Barraza J, et al
    Necroptotic astrocytes contribute to maintaining stemness of disseminated medulloblastoma through CCL2 secretion.
    Neuro Oncol. 2019 Nov 15. pii: 5626144. doi: 10.1093.
    PubMed     Abstract available


  419. CAPDEVIELLE C, Desplat A, Charpentier J, Saggliocco F, et al
    HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53.
    Neuro Oncol. 2019 Nov 10. pii: 5618834. doi: 10.1093.
    PubMed     Abstract available


  420. DRUMM MR, Dixit KS, Grimm S, Kumthekar P, et al
    Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.
    Neuro Oncol. 2019 Nov 10. pii: 5618827. doi: 10.1093.
    PubMed     Abstract available


  421. ARRILLAGA-ROMANY I, Odia Y, Prabhu VV, Tarapore RS, et al
    Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
    Neuro Oncol. 2019 Nov 8. pii: 5614983. doi: 10.1093.
    PubMed     Abstract available


  422. COOMANS MB, Dirven L, Aaronson NK, Baumert BG, et al
    Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?
    Neuro Oncol. 2019;21:1447-1457.
    PubMed     Abstract available


  423. WEI J, Chen P, Gupta P, Ott M, et al
    Immune biology of glioma associated macrophages and microglia: Functional and therapeutic implications.
    Neuro Oncol. 2019 Nov 3. pii: 5611251. doi: 10.1093.
    PubMed     Abstract available


  424. DAS A, Ramaswamy V
    Less treatment for Wingless Medulloblastoma: germline data re-emphasizes this.
    Neuro Oncol. 2019 Nov 3. pii: 5611252. doi: 10.1093.
    PubMed    


  425. FAN Q, An Z, Wong RA, Luo X, et al
    Betacellulin drives therapy-resistance in glioblastoma.
    Neuro Oncol. 2019 Nov 3. pii: 5611241. doi: 10.1093.
    PubMed     Abstract available


    October 2019
  426. VICTOR RR, Malta TM, Seki T, Lita A, et al
    Metabolic Reprogramming Associated with Aggressiveness Occurs in the G-CIMP-High Molecular Subtypes of IDH1mut Lower Grade Gliomas.
    Neuro Oncol. 2019 Oct 30. pii: 5609197. doi: 10.1093.
    PubMed     Abstract available


  427. SAUNDERS CN, Cornish AJ, Kinnersley B, Law PJ, et al
    Lack of association between modifiable exposures and glioma risk: A Mendelian randomisation analysis.
    Neuro Oncol. 2019 Oct 30. pii: 5609347. doi: 10.1093.
    PubMed     Abstract available


  428. BALASUBRAMANIAN SK, Sharma M, Venur VA, Schmitt P, et al
    Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
    Neuro Oncol. 2019 Oct 24. pii: 5606822. doi: 10.1093.
    PubMed     Abstract available


  429. PATEL SK, Hartley RM, Wei X, Furnish R, et al
    Generation of diffuse intrinsic pontine glioma mouse models by brainstem targeted in utero electroporation.
    Neuro Oncol. 2019 Oct 22. pii: 5602255. doi: 10.1093.
    PubMed     Abstract available


  430. YOGANANDA CGB, Shah BR, Vejdani-Jahromi M, Nalawade SS, et al
    A Novel Fully Automated Mri-Based Deep Learning Method for Classification of Idh Mutation Status in Brain Gliomas.
    Neuro Oncol. 2019 Oct 22. pii: 5602247. doi: 10.1093.
    PubMed     Abstract available


  431. SANTANA-CODINA N, Muixi L, Foj R, Sanz-Pamplona R, et al
    GRP94 promotes brain metastasis by engaging pro-survival autophagy.
    Neuro Oncol. 2019 Oct 22. pii: 5602253. doi: 10.1093.
    PubMed     Abstract available


  432. TESILEANU CMS, Dirven L, Wijnenga MMJ, Koekkoek JAF, et al
    Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
    Neuro Oncol. 2019 Oct 22. pii: 5602222. doi: 10.1093.
    PubMed     Abstract available


  433. IWATA R, Lee JH, Hayashi M, Dianzani U, et al
    ICOSLG-mediated regulatory T cell expansion and IL-10 production promote progression of glioblastoma.
    Neuro Oncol. 2019 Oct 22. pii: 5601905. doi: 10.1093.
    PubMed     Abstract available


  434. PLATTEN M
    Driving mesenchymal transition in glioblastoma.
    Neuro Oncol. 2019 Oct 19. pii: 5599736. doi: 10.1093.
    PubMed    


  435. JOHANNESSEN TA, Bjerkvig R
    A new chance for EGFR inhibition in glioblastoma?
    Neuro Oncol. 2019 Oct 19. pii: 5599734. doi: 10.1093.
    PubMed    


  436. GITTLEMAN H, Sloan AE, Barnholtz-Sloan JS
    An independently validated survival nomogram for lower grade glioma.
    Neuro Oncol. 2019 Oct 17. pii: 5588962. doi: 10.1093.
    PubMed     Abstract available


  437. BHATIA A, Birger M, Veeraraghavan H, Um H, et al
    MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors.
    Neuro Oncol. 2019 Oct 17. pii: 5588961. doi: 10.1093.
    PubMed     Abstract available


  438. IJAZ H, Koptyra M, Gaonkar KS, Rokita JL, et al
    Pediatric High Grade Glioma Resources from the Children's Brain Tumor Tissue Consortium (Cbttc).
    Neuro Oncol. 2019 Oct 15. pii: 5588066. doi: 10.1093.
    PubMed    


  439. ISLIM AI, Kolamunnage-Dona R, Mohan M, Moon RDC, et al
    A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas.
    Neuro Oncol. 2019 Oct 11. pii: 5585790. doi: 10.1093.
    PubMed     Abstract available


  440. RUBIN JB, Schlaggar BL
    To each, his/her own.
    Neuro Oncol. 2019;21:1217-1218.
    PubMed    


  441. WU CY, Chen CH, Lin CY, Feng LY, et al
    CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase-2.
    Neuro Oncol. 2019 Oct 8. pii: 5583889. doi: 10.1093.
    PubMed     Abstract available


  442. KOMORI T
    The anticipated revision of the grading criteria for adult isocitrate dehydrogenase-mutant diffuse glioma within the neuro-oncology community.
    Neuro Oncol. 2019 Oct 5. pii: 5581618. doi: 10.1093.
    PubMed    


    September 2019
  443. SU X, Chen N, Sun H, Liu Y, et al
    Automated Machine Learning Based on Radiomics Features Predicts H3 K27M Mutation in Midline Gliomas of the Brain.
    Neuro Oncol. 2019 Sep 29. pii: 5575985. doi: 10.1093.
    PubMed     Abstract available


  444. FU Y, Wang D, Wang H, Cai M, et al
    TSPO deficiency induces mitochondrial dysfunction, leading to hypoxia, angiogenesis and a growth-promoting metabolic shift towards glycolysis in glioblastoma.
    Neuro Oncol. 2019 Sep 29. pii: 5575982. doi: 10.1093.
    PubMed     Abstract available


  445. RIVERO-HINOJOSA S, Kinney N, Garner HR, Rood BR, et al
    Germline Microsatellite Genotypes Differentiate Children with Medulloblastoma.
    Neuro Oncol. 2019 Sep 28. pii: 5575474. doi: 10.1093.
    PubMed     Abstract available


  446. VERBURG N, Koopman T, Yaqub MM, Hoekstra OS, et al
    Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study.
    Neuro Oncol. 2019 Sep 24. pii: 5573318. doi: 10.1093.
    PubMed     Abstract available


  447. TANNOUS BA, Badr CE
    An allosteric inhibitor of SHP2 effectively targets PDGFRalpha-driven glioblastoma.
    Neuro Oncol. 2019 Sep 17. pii: 5570971. doi: 10.1093.
    PubMed    


  448. BASHIR A, Mathilde Jacobsen S, Molby Henriksen O, Broholm H, et al
    Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
    Neuro Oncol. 2019 Sep 6. pii: 5564094. doi: 10.1093.
    PubMed     Abstract available


    July 2019
  449. APPAY R, Dehais C, Maurage CA, Alentorn A, et al
    CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Neuro Oncol. 2019 Jul 12. pii: 5531923. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  450. WESSELING P
    The ABCs of molecular diagnostic testing of CNS tumors: acceptance, benefits, costs.
    Neuro Oncol. 2019;21:559-561.
    PubMed    


    February 2019
  451. BARNHOLTZ-SLOAN JS
    Brain and central nervous system tumor statistics: access to accurate data for all countries is critical!
    Neuro Oncol. 2019;21:291-292.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: